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Thesis directed by Professor Ding. Xue 
 
 
 
The nematode Caenorhabditis elegans has become a successful animal model for 
biomedical research, particularly in studying mechanisms of cell death and human disease. 
The conservation of critical biological pathways between C. elegans and higher organisms, 
together with the simplicity and cost-effectiveness of cultivation, make for an effective in 
vivo animal model that is amenable to genetic dissection and pharmacological 
manipulation. My thesis describes how I used C. elegans as an animal model to advance our 
understanding of caspase regulation and HBV pathogenesis.  
First I report that inactivation of the C. elegans csp-3 and csp-2 genes, which encode 
two proteins similar to the CED-3 caspase, causes somatic and germ cells that normally live 
to undergo apoptosis in a CED-3-dependent manner, respectively. Biochemical analysis 
reveals that both CSP-3 and CSP-2 associate with the CED-3 zymogen and inhibit zymogen 
auto-activation. However, neither CSP-3 nor CSP-2 blocks CED-3 activation induced by 
CED-4 nor inhibit the activity of the activated CED-3 protease.  Therefore CSP-3 and CSP-
2 employ a novel mechanism to protect somatic and germ cells from inadvertent apoptosis. 
Then I used C. elegans as an animal model to study the key pathogenic protein of 
HBV, HBx. I show that expression of HBx in C. elegans induces both necrotic and 
apoptotic cell death, mimicking an early event of liver infection by HBV. Genetic and 
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biochemical analyses indicate that HBx interacts directly with the Bcl-2 homolog CED-9, 
and triggers an increase in cytosolic Ca2+ and induction of both apoptosis and necrosis.  
Moreover, Bcl-2 binds HBx in human hepatic cells and can substitute for CED-9 in 
mediating HBx-induced cell killing in C. elegans, suggesting that CED-9 and Bcl-2 are 
conserved cellular targets of HBx. In addition, a genetic screen has been carried out to 
identify genes important for HBx-induced cell death. I report the identification of the vps-
29 gene, which encodes a retromer component, as an important regulator of HBx induced 
cell death in C. elegans. Loss of vps29 as well as other retromer components strongly and 
specifically reduced HBx induced ectopic cell death, suggesting that the retromer plays an 
important regulatory role in HBV replication and pathogenesis. 
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CHAPTER I 
Introduction 
 Despite its simplicity, the nematode Caenorhabditis elegans has developed into a 
successful and robust animal model for biomedical research, particularly in studying cell death 
mechanism and disease pathogenesis. The conservation of crucial cellular pathways between C. 
elegans and higher organisms, together with the simplicity and cost-effectiveness of cultivation, 
make for an effective in vivo model that is amenable to genetic dissection and pharmacological 
manipulation.  
 
C. elegans is a powerful experimental system for dissecting complex regulatory networks 
and conserved biological processes 
As a model organism, C. elegans is uniquely amenable to a combination of molecular 
genetic, cell biological, biochemical, and functional genomic studies and has provided a simple 
but powerful animal model for dissecting complex but conserved biological processes such as 
apoptosis, aging, and RNA interference (RNAi) (1). Besides the fact that C. elegans is easy and 
inexpensive to maintain in the laboratory, the only 1 mm long worm can be grown on agar plates 
with E. coli as food source, its short generation time and large broodsize make it a convenient 
model organism. C. elegans individuals are mainly hermaphrodites, which can reproduce by self-
fertilization and easy for maintaining; however, at low frequency, a spontaneous loss of the X 
chromosome at meiosis can result in males, which can fertilize hermaphrodites and therefore 
allow crosses between different strains. C. elegans is transparent making it possible to observe 
development at the cellular level even in the living individual (1). This is very convenient for 
studying apoptosis; dying cells can be observed directly using Differential Interference Contrast 
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(DIC) microscopy (Nomarski Optics) due to distinct morphological changes. The anatomical 
simplicity of this organism is another advantage: during the development of a C. elegans 
hermaphrodite 1090 somatic cells are generated, of which 131 cells are determined to die and 
subsequently undergo apoptosis. This lineage is essentially invariant, and therefore makes it easy 
to predict which cell is going to die at what time and position(2). Cell death is not essential for 
the viability of C. elegans, unlike in many other animals(3), which allowed the isolation and 
analysis of different cell death mutants. 
 
 
Cell death in C. elegans  
The genetic studies of apoptosis in C. elegans have been instrumental in identifying 
central cell-killing components and pathways (Fig. 1.1), which are highly conserved between C. 
elegans and humans (4).  These include CED-3/caspases, CED-4/Apaf-1, CED-9/Bcl-2, and 
EGL-1/BH3-only pro-apoptotic proteins (in C. elegans and humans, respectively).  Amazingly, 
so far every single gene involved in C. elegans apoptosis has at least one corresponding 
homologue in mammals playing a similar role. Similarly, the genetic analyses of aging in C. 
elegans have propelled rapid progresses in aging research and galvanized aging studies in other 
systems.  Again, many components involved in controlling life spans in C. elegans and mammals 
are conserved (5).  In both cases, genetic studies in C. elegans have led to identification of 
several good drug targets for treating various disease states, such as caspases as apoptosis drug 
targets and Foxo transcription factors as longevity targets (6). Therefore, C. elegans is an 
excellent system to dissect apoptosis. 
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Figure 1.1 Apoptosis pathways are conserved between C. elegans and Mammals. Both in mammals 
and in C. elegans, activation of pro-apoptotic EGL-1/BH3-only proteins initiates apoptosis by binding to 
and inhibiting the activities of CED-9/Bcl-2 family members.  This leads to the activation of CED-
4/Apaf-1, which in turn activates CED-3/caspases, the key enzymatic executioners of apoptosis. 
 
Although the necrotic cell death pathway in C. elegans is not as well studied as the 
apoptotic cell death pathway, several key components have been identified recently to be critical 
for mediating necrotic cell death in C. elegans (7).  These include proteins that regulate Ca2+ 
homeostasis such as the endoplasmic reticulum (ER) Ca2+ binding proteins calreticulin (CRT-1) 
and calnexin (CNX-1), calcium channels inositol triphosphate receptor (ITR-1) and UNC-68 
(uncoordinated, a ryanodine receptor homolog), Ca2+-regulated calpain proteases CLP-1 and 
TRA-3, and cytoplasmic aspartyl proteases ASP-3 and ASP-4 (Fig. 1.2).  These necrosis 
regulators are thought to be conserved components of mammalian necrosis pathways as well 
(Figure 1.2). 
 
Figure 1.2 The necrotic cell death pathway in C. elegans. 
 
  
 
Caspases and caspase regulators 
An essential component of the apoptotic machinery is the caspase, a family of cysteine 
proteases that execute apoptosis by cleaving specific cellular protein substrates after Aspartate 
residues(8).  All caspases are initially synthesized as latent zymogens, each comprising an 
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amino-terminal prodomain and two catalytic subunits known as the large and the small 
subunits(8).  The activation of the caspase zymogens proceeds by auto-proteolysis through 
induced dimerization or oligomerization of the caspase zymogens or proteolytic cleavage by 
upstream caspases or cysteine proteases(9, 10). Once activated, caspases cleave a broad spectrum 
of cellular targets, leading to the demise of the cell. 
 
Given the crucial roles of caspases in apoptosis, it is critical that their activities be tightly 
regulated.  The control of caspase activity can be achieved at two different levels, the activation 
of caspase zymogens and the catalytic activity of activated caspases, and by both positive and 
negative regulators(11).  Since caspases are widely expressed in many cells(12), elaborate 
mechanisms must be in place to prevent inadvertent activation of caspases in cells that normally 
live.  In cells that receive apoptotic stimuli or cells that are destined to die, positive regulators are 
unleashed to promote the activation of caspase zymogens. One such positive regulator is 
mammalian Apaf-1, which activates the caspase-9 zymogen through formation of an oligomeric 
apoptosome upon the release of cytochrome c from mitochondria(13-15).  In C. elegans, the 
Apaf-1 homologue CED-4 activates the CED-3 zymogen through a similar oligomerization 
event, after the cell death initiator EGL-1 binds to the cell death inhibitor CED-9 and triggers the 
dissociation of the CED-4 dimer from CED-9 tethered on the surface of mitochondria(16-20).  
These observations suggest that the general mechanisms of caspase activation are conserved 
from C. elegans to mammals, although the details may vary in different organisms(9, 10). 
 
To prevent inadvertent cell death, various negative regulators of apoptosis are employed by 
cells to keep the apoptotic machinery in check.  For example, the cell death inhibitors Bcl-2 or 
Bcl-xL and their worm homolog CED-9 prevent Apaf-1 and CED-4 from forming oligomeric 
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apoptosomes in mammals and C. elegans, respectively(15, 21). The inhibitor of apoptosis 
proteins (IAPs), characterized by at least one baculoviral IAP repeat (BIR) and a RING finger 
motif(22), are dedicated negative regulators of caspases in Drosophila and higher organisms(23-
27).  IAP proteins have been shown to directly inhibit the activation of caspase zymogens as well 
as the catalytic activity of activated caspases(22, 28-30).  Intriguingly, no IAP homologue or 
caspase inhibitor has been identified in C. elegans, whereas other key components of apoptosis 
were found to be highly conserved(4), I am very interested in investigating how the activation 
and the activity of the CED-3 caspase are regulated in C. elegans.   
 
Germline cell death in C. elegans 
In C. elegans, a lot of early developing germ cells undergo apoptosis during normal 
oogenesis; this process is called germline apoptosis(31, 32). Germline apoptosis appears to be an 
integral component of the oogenesis program and has been suggested to be important for 
eliminating excess germ cells that acted as nurse cells to provide cytoplasmic components to 
maturing oocytes(31-33). Germline apoptosis is conserved among eukaryotes, from C. elegans to 
humans. Therefore, C. elegans provides an excellent model system for studying the regulation of 
germ cell apoptosis. 
The molecular machinery that mediates germline apoptosis has been extensively studied 
and found to share key components with that of somatic apoptosis.  In particular, CED-3, CED-4 
and CED-9 are essential for apoptosis in both germ cells and somatic cells(31, 32). However, 
regulation of apoptosis in germ cells and in somatic cells appears to differ significantly.  For 
example, the pro-apoptotic BH3 only protein EGL-1 is crucial for somatic apoptosis but is 
dispensable for physiological germ cell death(31). Moreover, C. elegans somatic cells are 
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resistant to genotoxic insults, whereas germ cells readily respond to genotoxic stresses to 
undergo apoptosis(34), suggesting that the regulation of germ cell death could be fundamentally 
different from that of somatic cell death. I am interested in investigating the difference of 
regulation between somatic and germ cell death.   
 
HBV, HBx, liver cell death, and liver diseases 
The hepatitis B virus (HBV) infects the liver and causes acute and chronic hepatitis. 25% 
of the adults who acquire chronic hepatitis B during childhood die from cirrhosis or 
hepatocellular carcinoma (HCC)(35). It is estimated that 400 million individuals worldwide live 
with chronic HBV infection, primarily in Asia, Africa, and the developing world, 1.25 million of 
which live in the United States (36, 37).  Therefore, HBV remains a major public health problem.  
 
HBV belongs to the hepadnaviridae family of viruses. The natural host for HBV is 
humans, though much of what I know about HBV comes from the study of similar viruses 
isolated from ape, woodchuck, geese, and duck, all of which are poor and undesirable animal 
models for basic and therapeutic research and mechanistic studies (36). The 3.2 kb HBV genome 
contains four overlapping open reading frames that encode the viral surface antigens (HBsAgs), 
core protein (HBcAg), polymerase/reverse-transcriptase, and the X protein (HBx). HBsAgs coat 
the viral envelope before virion secretion and are important for viral entry into host cells.  
HBcAg is necessary for viral packaging before HBV virion secretion. Polymerase is important 
for viral replication and promotes capsid maturation (36).  HBx is perhaps the most enigmatic 
aspect of HBV infection and pathogenesis. The HBx gene encodes a 17kD protein that is 
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conserved in all mammalian hepadnaviruses. However, the designation of X protein reflects its 
poorly characterized in vivo function and lack of homology with any known host protein (38).  
 
HBx appears to be a multi-functional viral protein that can regulate HBV replication, 
cellular transcription and signal transductions, proteasome activity, cell cycle progression, and 
cell death (38, 39).  As a key regulatory protein of HBV, HBx has been shown by many studies 
to play an important role in neoplastic transformation of hepatocytes in HBV-infected livers.  For 
example, HBx expression is detected in the majority of patients with HBV-related HCC and is 
the most frequently integrated viral sequence found in HCC (39). Moreover, in several studies, 
high incidences of transgenic mice expressing only HBx develop liver tumors, revealing a causal 
relationship between HBx and HCC (38, 40).  However, how liver expression of HBx leads to 
development of HBV-associated HCC is poorly understood. Adding to the puzzle, HBx has been 
found to bind a vast number of proteins in various in vitro systems, including many factors 
involved in transcription, some components of the proteosome, mitochondria-related proteins, 
and cell cycle regulators such as p53 (37, 41). Unfortunately, most of these interactions could not 
be confirmed under conditions that recapitulate HBV infection in hepatocytes. As a result, the in 
vivo targets of HBx remain elusive (38). Therefore, development of an animal model that can 
facilitate the identification of HBx cellular targets is of vital importance to therapeutic prevention 
and treatment of HBV-associated liver diseases. 
 
Many studies have linked HBx expression to the activation of apoptosis and necrosis in 
liver cells (38, 42). For example, HBx can sensitize liver cells to apoptosis by tumor necrosis 
factor-∂ (TNF-∂) and can induce mitochondrial aggregation and cytochrome c release, indicating 
that induction of apoptosis is caused by mitochondria dysfunction (43, 44). Apoptosis and 
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necrosis are also early events of liver pathogenesis in HBx transgenic mice that lead to 
development of liver cirrhosis and HCC (45, 46).  While all these reports strongly suggest a cell 
death inducing function for the HBx protein, it is unclear how HBx-mediated apoptosis/necrosis 
contributes to the development of HCC and what are HBx cellular targets for apoptosis and 
necrosis.  It has been hypothesized that chronic hepatocyte cell death causes repeated local liver 
repair and release of inflammatory cytokines that promote hepatocyte proliferation, leading to 
the acquisition of oncogenic mutations and enhancement of hepatocarcinogenesis (46, 47). 
Blocking HBV-induced liver cell deaths could present a very effective intervention point in 
preventing the development of liver diseases and in treating liver disorders (including HCC) in 
HBV chronic carriers and patients. Therefore, identification of HBx cellular targets has become a 
critically important issue in HBV therapy.  
 
Thesis Aims 
As described above, there is no IAP homologue or direct caspase inhibitor identified in C. 
elegans. It is thus enigmatic how the activity of the CED-3 caspase, the key cell killing protein, 
is controlled in C. elegans so that it is prevented from inadvertent activation in somatic and 
germline cells that normally live. Also, not much is known about how HBx, the key pathogenic 
protein of HBV, acts in the host cells and what are its actual cellular targets. 
 
Taken together, the aims of my thesis was to obtain insights about how the activity of the 
CED-3 caspase is controlled in C. elegans to prevent inadvertent activation of caspase and to 
develop a C. elegans model where HBx host factors and downstream effectors can be identified 
and verified through powerful molecular genetic approaches in order to understand HBx 
functions and ultimately leading to novel treatment for chronic HBV patients. 
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CHAPTER II 
Inhibition of CED-3 zymogen activation and apoptosis in Caenorhabditis elegans by a 
caspase homolog CSP-3 
 
 
ABSTRACT 
Inhibitor of apoptosis (IAP) proteins play a critical role in apoptosis, through negative 
regulation of caspases in diverse species from fruit flies to mammals.  In Caenorhabditis 
elegans, however, no IAP homologue or caspase inhibitor has been identified, calling into 
question of how the cell-killing caspase CED-3 can be negatively regulated. Here I show that 
inactivation of the C. elegans csp-3 gene, which encodes a protein similar to the small subunit of 
the CED-3 caspase, causes cells that normally live to undergo apoptosis in a CED-3-dependent 
manner. Biochemical analysis reveals that CSP-3 associates with the large subunit of the CED-3 
zymogen and inhibits zymogen auto-activation. However, CSP-3 does not block CED-3 
activation by CED-4 nor inhibit the activity of the activated CED-3 protease.  Therefore CSP-3 
employs a previously unreported mechanism to protect cells from apoptosis. 
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INTRODUCTION  
  Apoptosis is a fundamental process in the development and tissue homeostasis of 
metazoans(48).  During apoptosis, a suicide machinery is activated to dismantle the cell(48). An 
essential component of the apoptotic machinery is the caspase, a family of cysteine proteases that 
execute apoptosis by cleaving specific cellular protein substrates after Aspartate residues(8).  All 
caspases are initially synthesized as latent zymogens, each comprising an amino-terminal 
prodomain and two catalytic subunits known as the large and the small subunits(8).  The 
activation of the caspase zymogens proceeds by auto-proteolysis through induced dimerization 
or oligomerization of the caspase zymogens or proteolytic cleavage by upstream caspases or 
cysteine proteases(9, 10). Once activated, caspases cleave a broad spectrum of cellular targets, 
leading to the demise of the cell. 
 
Given the crucial roles of caspases in apoptosis, it is imperative that their activities be 
tightly regulated.  The control of caspase activity can be achieved at two different levels, the 
activation of caspase zymogens and the catalytic activity of activated caspases, and by both 
positive and negative regulators(11).  Since caspases are widely expressed in many cells(12), 
elaborate mechanisms must be in place to prevent inadvertent activation of caspases in cells that 
normally live.  In cells that receive apoptotic stimuli or cells that are destined to die, positive 
regulators are unleashed to promote the activation of caspase zymogens. One such positive 
regulator is mammalian Apaf-1, which activates the caspase-9 zymogen through formation of an 
oligomeric apoptosome upon the release of cytochrome c from mitochondria(13-15).  In 
Caenorhabditis elegans, the Apaf-1 homologue CED-4 activates the CED-3 zymogen through a 
similar oligomerization event, after the cell death initiator EGL-1 binds to the cell death inhibitor 
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CED-9 and triggers the dissociation of the CED-4 dimer from CED-9 tethered on the surface of 
mitochondria(16, 18-20, 49).  These observations suggest that the general mechanisms of 
caspase activation are conserved from C. elegans to mammals, although the details may vary in 
different organisms(9, 10). 
 
To prevent inadvertent cell death, various negative regulators of apoptosis are employed by 
cells to keep the apoptotic machinery in check.  For example, the Bcl-2 family cell death 
inhibitors and their worm homolog CED-9 prevent Apaf-1 and CED-4 from forming oligomeric 
apoptosomes in mammals and C. elegans, respectively(15, 21). The inhibitor of apoptosis 
proteins (IAPs), characterized by at least one baculoviral IAP repeat (BIR) and a RING finger 
motif(22), are dedicated negative regulators of caspases in Drosophila and higher organisms(23-
27).  IAP proteins have been shown to directly inhibit the activation of caspase zymogens as well 
as the catalytic activity of activated caspases(22, 28-30).  Intriguingly, no IAP homologue or 
caspase inhibitor has been identified in C. elegans, whereas other key components of apoptosis 
were found to be highly conserved(4), raising an important question of how the activation and 
the activity of the CED-3 caspase are regulated in C. elegans.  Here, I show that the product of 
the csp-3 gene, a protein similar to the small subunit of CED-3, functions as a direct caspase 
inhibitor to prevent cells that normally live from apoptosis. 
 
RESULTS 
Loss of csp-3 causes increased cell deaths 
csp-3 is one of the three additional caspase-like genes in C. elegans that have no known 
functions(50). Unlike regular caspases, CSP-3 does not contain a caspase large subunit with an 
active site Cysteine and is predicted to lack proteolytic activity.  Its sequence similarity to the 
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small subunits of caspases and the fact that the small and the large subunits of caspases form 
heterotetramers during caspase activation suggest that CSP-3 may associate with other caspases 
such as CED-3 and modulate the activation of CED-3 (Fig. 2.1a).  To investigate the function of 
csp-3 in C. elegans, I generated two deletion alleles of csp-3, tm2260 and tm2486.  tm2260 
removes a 193 base pair (bp) region of the csp-3 gene, including the last exon and part of the 3’ 
untranslated region (UTR).  tm2486 contains a 713 bp deletion that almost removes the entire 
coding region of csp-3 (Fig. 2.1b).  Both deletions abolished the expression of csp-3 in C. 
elegans and are putative null alleles (Fig. 2.1c).  
 
Figure 2.1.  CSP-3 is a cytoplasmic protein with sequence homology to the small subunit of CED-3.  
(a) Sequence alignment of CSP-3 and small subunits of CED-3 and human caspase-3. Residues that are 
identical are shaded in yellow and residues that are similar in pink. Phe 57 of CSP-3 is indicated with a 
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blue arrowhead.  (b) The csp-3 gene structure and deletion mutations.  Exons are depicted as boxes and 
introns as lines.  The translated regions of csp-3 are highlighted in blue. Two orange boxes indicate the 
regions of csp-3 removed by the two csp-3 deletions, respectively. Also shown are a csp-3 translational 
gfp fusion and a 5.73 kb genomic rescuing fragment [csp-3(+)].  (c) Both csp-3 deletions abolish 
expression of csp-3 in C. elegans. Immunoblotting for CSP-3 in total worm lysates from N2, csp-
3(tm2260), and csp-3(tm2486) animals.  The CstF-64 protein was used as a loading control.  (d) csp-3 is 
ubiquitously expressed in C. elegans embryos.  Differential Interference Contrast (DIC) and GFP images 
of an early stage embryo carrying Pcsp-3csp-3::gfp are shown. 
 
 
 
I first examined if cell death occurred normally in csp-3(tm2486) and csp-3(tm2260) 
animals by counting cells present in the anterior pharynx of these animals. Among 29 cells that 
normally live (Table 2.1), approximately 40% of csp-3 mutant animals were missing one or two 
cells, whereas cells that normally die were unaffected (data not shown).  To investigate the cause 
of missing cells in csp-3 mutants, I counted the number of apoptotic cell corpses in various 
embryonic stages and found that csp-3(tm2486) and csp-3(tm2260) animals had slightly higher 
numbers of apoptotic cells in some embryonic stages than wild-type animals (Fig. 2.2a).  Since 
apoptotic cells are swiftly engulfed in C. elegans by their neighboring cells, this assay would not 
detect a small increase in apoptosis. I thus constructed double mutants containing a csp-3 
mutation and a mutation that partially disables cell corpse engulfment such as ced-5(n1812) or 
ced-6(n2095)(51).  The csp-3; ced-5 and csp-3; ced-6 double mutants had substantially more cell 
corpses in most embryonic stages and in the L1 larval stage than ced-5, ced-6, or csp-3 single 
mutants (Fig. 2.2b, c).  The increased numbers of cell corpses in csp-3; ced-5 and csp-3; ced-6 
double mutants indicate that csp-3 mutations either result in increased cell deaths or compromise 
cell corpse engulfment.  Since cells that normally live were missing in the csp-3 mutants (Table 
2.1), these results are more consistent with csp-3 mutations causing ectopic cell deaths. 
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Table 2.1  csp-3 mutations cause missing cells 
% of normal cells missing b Genotype Extra cell 
Average a 
Missing cell 
Average a m2 I1 m1 MC NSM I3 Others 
N2 0.0 + 0.0 0.0 + 0.0 0 0 0 0 0 0 0 
csp-3(tm2260) 0.0 + 0.0 0.5 + 0.2 0 10 2.5 7.5 0 0 0 
csp-3(tm2486) 0.0 + 0.0 0.6 + 0.1 0.8 5.0 1.3 12.5 2.5 5.0 0 
ced-3(n2438) 1.8 + 0.3 0.0 + 0.0 0 0 0 0 0 0 0 
csp-3(tm2260); 
ced-3(n2438) 
1.7 + 0.3 0.3 + 0.1 0 5.0 0 7.5 0 0 0 
csp-3(tm2486); 
ced-3(n2438) 
1.8 + 0.3 0.4 + 0.1 0 5.0 3.8 2.5 2.5 0 0 
a The number of cells that are programmed to die but inappropriately survive (extra cell) or the number of 
cells that normally live but are missing (missing cell) was scored in the anterior pharynx of L4 
hermaphrodites using Nomarski optics.  Data shown are mean + s.e.m.  20 animals were scored in each 
strain. 
b The percentage of specific cells in the anterior pharynx that normally live but are missing is shown (the 
number of missing cells of a specific cell type divided by the total number of specific cells expected).  
Miss cells were observed in the following cell types: 6 m2 muscle cells, 2 I1 neurons, 4 m1 muscle cells 
in two ventral planes, 2 MC neurons, 2 NSM neurons, and one I3 neuron.  Miss cells were not observed 
in the following cell types (named others): 3 e2 epithelial cells, 3 e1 epithelial cells, 2 I2 neurons, one 
M4 neuron, one MI neuron, and 2 m1 muscle cells in the dorsal plane. 
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Figure 2.2  Loss of csp-3 results in increased cell deaths during embryo development. (a-c) Cell 
corpses were scored in the indicated strains. ced-5(n1812) and ced-6(n2096) alleles were used in b and c, 
respectively. Bean (B/C), 1.5-fold (1.5), 2-fold (2), 2.5-fold (2.5), 3-fold (3), 4-fold (4) stage embryos and 
L1 larvae (L1) were examined.  (d) Rescue of the csp-3 mutant by various transgenes.  4-fold stage 
embryos from csp-3(tm2260); ced-5(n1812) animals carrying the indicated transgenes were scored for 
cell corpses.  In a-d, the y axis represents the average number of cell corpses scored. Error bars are 
standard deviation (SD).  15 embryos or larvae were scored for each stage or transgenic line. In a-c, the 
significance of differences in two different genetic backgrounds at multiple developmental stages was 
determined by analysis of variance and Fisher probable least-squares difference.  * P < 0.05, ** P < 
0.0001. All other points had P values > 0.05.  In d, data from two independent transgenic lines were 
analyzed similarly and compared with that of csp-3(tm2260); ced-5(n1812) animals. * P < 0.05, ** P < 
0.0001.  (e) Western blot analysis of the expression levels of CSP-3 in two Psur-5csp-3 transgenic lines 
(line 1 and lines 2) compared with that of wild-type animals (N2) or csp-3(tm2260) animals.  (f) 
Overexpression of CSP-3 in C. elegans mildly inhibits programmed cell death.  Extra undead cells in the 
anterior pharynx were scored in two Psur-5csp-3 transgenic lines and two control Psur-5gfp transgenic lines.  
At least 15 transgenic animals were scored for each strain. 
 
 
 
The increased cell corpse phenotype in csp-3(tm2260); ced-5(n1812) animals could be 
rescued through germline transformation by a 5.73 kb genomic fragment containing the csp-3 
coding region flanked by 4149 bp promoter and 1017 bp 3’ untranslated region (Fig. 2.1b and 
Fig. 2.2d).  I could also rescue the csp-3 mutants by ubiquitously expressing csp-3 under the 
control of the dpy-30 gene promoter (Pdyp-30csp-3) or the sur-5 gene promoter (Psur-5csp-3; Fig. 
 16 
2.2d)(52, 53), suggesting that loss of the csp-3 activity causes increased apoptosis.  The Psur-5csp-
3 transgene, which caused widespread overexpression of csp-3 in C. elegans (Fig. 2.2e), only 
mildly inhibited normal programmed cell death in wild-type animals (Fig. 2.2f).  In addition, loss 
of csp-3 did not reduce the number of cells that escape apoptotic cell fates in the anterior 
pharynx of ced-3(n2438) animals, which is partially defective in cell death, but still caused loss 
of normal cells, albeit at a reduced frequency (Table 2.1).  These observations suggest that csp-3 
protects cells that normally live but does not seem to affect cells that are destined to die. 
 
csp-3 protects cells that normally live from apoptosis  
I further characterized the missing cell phenotype of the csp-3 mutants using various 
integrated transgenes carrying GFP reporters that label different cells or cell types and thus allow 
clear identification of the cells that are lost in the csp-3 mutants.  For example, the Pmec-4gfp 
construct in the bzIs8 transgene specifically labels six touch-receptor neurons(54).  In csp-3(lf); 
bzIs8 animals, all six touch cells were randomly lost (at a frequency from 2% to 10%; Fig. 2.3a) 
and 30-34% of animals lost at least one touch cell (data not shown).  The dying touch cells in the 
csp-3 mutants displayed raised button-like morphology characteristic of apoptotic cells (Fig. 
2.3b).  The missing cell defect in csp-3 mutants was rescued by the 5.73 kb csp-3(+) transgene 
(Fig. 2.3c) and was strongly suppressed by loss-of-function mutations in the egl-1, ced-4 and 
ced-3 genes (Fig. 2.3a), all of which are essential for C. elegans programmed cell death(4).  A 
similar percentage of animals (37-39%) randomly lost at least one neuron in csp-3(lf); inIs179 
animals,  in which different sets of neurons including the phasmid neurons (PHA, PHB and 
PHC), ventral cord neurons (VC), hermaphrodite-specific neurons (HSN), and ADE neurons 
were labeled by the Pida-1gfp reporter present in the inIs179 transgene (Fig. 2.3d) (55). Again, 
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such cell loss was strongly suppressed by a loss-of-function mutation (n2433) in the ced-3 gene 
(Fig. 2.3d).  Since the missing neurons are cells that normally live, these results confirm that csp-
3 plays an important role in protecting cells that normally live from apoptosis.  
 
 
Figure 2.3  Loss of csp-3 causes cells that normally live to undergo programmed cell death.  (a) 
Touch receptor neurons are randomly lost in csp-3 mutants via programmed cell death.  An integrated 
transgene (bzIs8) was used to monitor the survival of six touch receptor neurons (green circles) as 
described in METHODS. The percentage of a specific touch cell type lost was shown.  At least 100 
animals were scored for each strain.  (b) A PLM neuron labeled by GFP in a csp-3(tm2260); ced-
5(n1812); bzIs8 larva undergoes ectopic cell death and adopts a raised-button-like morphology 
characteristic of apoptotic cells (indicated by an arrow).  (c) The csp-3(+) transgene rescues the missing 
cell defect of the csp-3(tm2260) mutant. Touch cells were scored as described in a.  The percentage of 
animals missing at least one touch cell is shown.  (d) Several different types of neurons are also randomly 
lost in csp-3 mutants.  An integrated transgene (inIs179) was used to label sixteen neurons (green circles) 
in all strains examined.  The presence of these neurons in L4 larvae was scored using a Nomarski 
microscope equipped with epifluorescence.  The percentage of a specific cell type missing was calculated 
as follow: the number of cells missing in a cell type divided by the number of total cells expected in a cell 
type.  The specific cell types are: two ADE neurons, six ventral cord neurons (VC), two HSN neurons, six 
phasmid (PH) neurons (two PHA, two PHB and two PHC). The percentage of animals missing at least 
one neuron is also shown.  At least 100 animals were scored for each strain. 
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Loss of csp-3 causes low percentage embryonic lethality  
I also examined whether random loss of living cells in csp-3 mutants might result in 
developmental abnormalities, such as those seen in animals defective in another anti-apoptosis 
gene ced-9(56). I found that 5-6% of csp-3 mutant embryos failed to hatch and approximately 
2% of csp-3 mutant animals displayed uncoordinated body movement (Unc), compared with 
only 0.2% embryonic lethality and 0% Unc observed in wild-type animals (Table 2.2).  These 
defects are similar to but substantially weaker than those seen in ced-9(lf) animals such as the 
temperature-sensitive ced-9(n1653) mutant(56) and can be partially suppressed by a weak ced-
3(n2438) mutation, suggesting that these defects result from ectopic cell deaths.  Moreover, csp-
3(tm2260) and csp-3(tm2486) mutations could exacerbate the defects of ced-9(n1653) animals 
(Table 2.2), resulting in almost complete sterility and lethality, suggesting that both genes are 
important for animal viability. 
 
Table 2.2  The csp-3 mutations cause embryonic lethality and uncoordinated body 
movement 
Genotype Eggs laid 
per animal a 
% embryonic 
lethality a 
Uncoordinated 
(%) a 
N2   209 + 13.0 0.2 + 0.1 0.0 + 0.0 
csp-3(tm2260) 152 + 7.9 5.0 + 0.3 b 2.1 + 1.0 c 
csp-3(tm2486) 155 + 9.4 5.9 + 0.3 b 1.7 + 0.7 c 
ced-9(n1653ts)  10.7 + 2.5 20.4 + 1.5 ND† 
ced-3(n2438) 166 + 4.5 1.0 + 0.4 0.0 + 0.0 
csp-3(tm2260); ced-3(n2438)   157 + 12.6 1.6 + 0.2 0.6 + 0.2 
csp-3(tm2486); ced-3(n2438)   158 + 13.4 1.5 + 0.2 0.7 + 0.1 
csp-3(tm2260); ced-9(n1653ts)    0.8 + 0.5 58.7 + 5.5 ND d 
csp-3(tm2486); ced-9(n1653ts)    0.9 + 0.3 59.6 + 5.1 ND d 
 ced-9(n1653ts); smIs179 12 + 2.5 17.6 + 1.9 ND d 
csp-3(tm2260); ced-9(n1653ts); 
smIs179 
6.8 + 2.0 37.9 + 2.3 ND d 
a All strains were maintained at 25°C.  The number of eggs laid by hermaphrodite animals, the number of eggs that 
hatched, and the number of animals that showed uncoordinated body movement were scored as described in 
METHODS.  The percentage of embryonic lethality was scored as the fraction of eggs laid that did not hatch(56).  
Strong loss-of-function mutations in ced-3 or ced-4 also cause some embryonic lethality(56) and thus cannot be used 
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to suppress embryonic lethality of csp-3(lf) embryos.  smIs179 is an integrated transgene containing the Pcsp-
3flag::csp-3 construct that rescues the missing cell defect of the csp-3 mutants (data not shown).  Data shown are 
mean + S.D. and are derived from three independent experiments.  For results shown in the 2nd and 3rd columns, 20 
animals were scored in each experiment.  For results shown in the fourth column, at least 90 animals were scored in 
each experiment.   
b Compared with N2 animals, P < 0.001 (two-tail student t test).  Compared with csp-3(lf); ced-3(n2438) animals, P 
< 0.005 
c Compared with N2 animals, P < 0.01.  Compared with csp-3(lf); ced-3(n2438) animals, P < 0.05. 
d ND, not determined.  ced-9(n1653) animals are sick at 25°C and the Unc phenotype cannot be reliably scored. 
 
 
CSP-3 is widely expressed during C. elegans development.   
To examine the expression pattern of csp-3, I generated a csp-3::gfp translational fusion 
(Pcsp-3csp-3::gfp) that contains 4149 bp of the csp-3 promoter (Fig. 2.1b).  This fusion construct 
fully rescued the missing cell phenotype of the csp-3 mutants (Fig. 2.2d), suggesting that the 
fusion protein is expressed in the right cells and targeted to the appropriate cellular location. 
CSP-3 is widely expressed in all cells of C. elegans embryos and its expression persists through 
the larval stages (Fig. 2.1d; and data not shown). CSP-3::GFP localizes in the cytoplasm and is 
excluded from the nucleus (Fig. 2.1d).  The localization and expression patterns of CSP-3 are 
consistent with its role in protecting cells that normally live from apoptosis. 
 
CSP-3 associates with CED-3.  
Given the sequence similarity between CSP-3 and the small subunit of CED-3, I tested 
whether CSP-3 may associate with CED-3 in vitro.  I co-expressed the CED-3 zymogen tagged 
with a Flag epitode and a glutathione S transferase (GST) CSP-3 fusion in bacteria and carried 
out GST fusion protein pull-down assays.  Under the condition of limited induction of protein 
expression, CED-3 existed as an unprocessed zymogen and GST-CSP-3, but not GST, 
specifically pulled down the CED-3 zymogen (Fig. 2.4a). 
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Figure 2.4  CSP-3 associates with CED-3 in vitro and in C. elegans.  (a) CSP-3 binds to the CED-3 
zymogen.  GST-CSP-3, GST-CSP-3(F57D), or GST was co-expressed in bacteria with the CED-3 
zymogen tagged with a Flag epitode (CED-3-Flag).  One portion of the soluble fraction was used in the 
western blot analysis to examine the expression levels of GST fusion proteins and CED-3-Flag using anti-
GST and anti-Flag antibodies, respectively.  The remaining portion of the soluble fraction was used in the 
GST fusion protein pulldown experiment and the amount of CED-3-Flag pulled down was analyzed by 
the western blot analysis using an anti-Flag antibody.  (b) CSP-3 associates specifically with the large 
subunit of CED-3 in vitro. GST-CSP-3, GST-CSP-3(F57D), or GST was co-expressed in bacteria with 
the CED-3 large subunit (p17) or the small subunit (p13), both of which are tagged with a Flag epitode 
(green box).  Analysis of the expression levels of GST fusion proteins and the two CED-3 subunits as 
well as the amounts of two CED-3 subunits co-precipitated with GST fusion proteins was conducted as 
described in a.  The diagram above depicts the domain structure of the CED-3 zymogen, with arrows 
indicating the three proteolytic cleavage sites needed to activate the CED-3 zymogen. The three CED-3 
cleavage products are shown below as boxes.  (c) CSP-3 associates with CED-3 in C. elegans.  Lysates 
from C. elegans animals expressing CED-3::GFP or CEH-30::GFP were prepared as described in 
METHODS.  One portion of the worm lysate was used in the western blot analysis to examine the 
expression levels of CSP-3 and GFP fusion proteins using anti-CSP-3 and anti-GFP antibodies, 
respectively. The remaining portion of the lysate was incubated with a mouse anti-GFP monoclonal 
antibody and precipitated using Protein G Sepharose beads.  The amount of the CSP-3 protein pulled 
down with the GFP fusion proteins was analyzed by the western blot analysis using purified anti-CSP-3 
antibody.  Very little full-length CED-3::GFP fusion was detected in the lysate (data not shown). The 
predominant species detected was a CED-3::GFP fusion without its prodomain but containing both large 
and small subunits.   
 
I further characterized the interaction between CSP-3 and CED-3 by examining the 
binding of CSP-3 to different domains of the CED-3 zymogen (Fig. 2.4b).  I found that the large 
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subunit of CED-3 was sufficient to mediate binding to CSP-3, whereas the N-terminal pro-
domain and the small subunit of CED-3 did not show detectable binding to CSP-3 (Fig. 2.4b; 
data not shown).  These results suggest that CSP-3 may mimic the small subunit of CED-3 to 
interact with the large subunit of CED-3 and thus interfere with the pro-apoptotic function of 
CED-3. 
 
I also examined whether CSP-3 associates with CED-3 in vivo by performing co-
immunoprecipitation assays using an integrated transgene (smIs10) carrying a ced-3::gfp 
translational fusion (Pced-3ced-3::gfp).  smIs10 can fully rescue the cell death defect of the ced-
3(lf) mutants (Table 2.3), suggesting that the CED-3::GFP fusion is functional.  Using a 
monoclonal antibody to GFP, I co-precipitated the CSP-3 protein with CED-3::GFP from the 
lysate of smIs10 animals (Fig. 2.4c).  In contrast, no CSP-3 was co-precipitated with another 
GFP fusion, CEH-30::GFP(57), from the lysate of smIs54 animals, which carried the ceh-30::gfp 
translational fusion (Fig. 2.4c).  Therefore, CSP-3 physically associates with CED-3 both in vitro 
and in vivo.  
 
Table 2.3 The smIs10 transgene rescues the ced-3(lf) defect 
Genotype No. of cell corpses a Range of corpses 
ced-1(e1735) 31.2 ± 1.4 29~34 
ced-1(e1735); ced-3(n717)   2.0 ± 1.3 0~4 
ced-1(e1735) smIs10; ced-3(n717) 31.4 ± 2.4 27~36 
a Cell corpses were scored at the 4-fold embryonic stages.  Data shown are mean ± S.D. 20 embryos from 
each strain were scored. 
 
 
   To identify CSP-3 residues that are important for binding to CED-3, I constructed a 
three-dimensional structural model of the CED-3-large subunit/CSP-3 complex based on the 
crystal structure of active caspase-3 (Fig. 2.5a)(58). Several single amino acid substitutions 
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(Phe57 to Asp, Ile76 to Asp, Ala87 to Glu, and Leu130 to Glu) were generated in CSP-3 using 
the modeled complex as a guideline and assessed for their abilities to affect CSP-3 binding to 
CED-3 in vitro (data no shown).  Alteration of one relatively conserved residue, Phe57, in CSP-3 
to Asp (F57D; Figure 2.1a) remarkably reduced the binding of CSP-3 to the CED-3 zymogen or 
the large subunit of CED-3 in vitro (Fig. 2.4a, b).  Importantly, transgenes expressing this CSP-
3(F57D) mutant [Pdpy-30CSP-3(F57D)] could hardly rescue the ectopic cell death defect of the 
csp-3 mutant, whereas transgenes expressing the wild-type CSP-3 protein (Pdpy-30CSP-3) at a 
similar level were able to do so (Fig. 2.2d and Fig. 2.5b).  These results indicate that association 
of CSP-3 with CED-3 is important for CSP-3 to protect cells that normally live from apoptosis. 
 
Figure 2.5.  (a) Three-dimensional structural model of the CED-3/CSP-3 complex. CED-3 large subunit 
is shown in green, CED-3 small subunit in cyan, and CSP-3 in magenta. CSP-3 complexes with the CED-
3 zymogen and blocks CED-3 auto-activation by homo-dimerization. The crystal structure of caspase-
3(PDB code 1pau) was used as the starting model. Based on the caspase sequence alignment (Fig.2.1a), 
the amino acids in the large and small subunits of caspase-3 are replaced by those in CED-3 and CSP-3, 
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respectively, in the graphics program O. The orientations of side chains were manually adjusted before 
the modeled structure of the CED-3 large subunit/CSP-3 heterodimer was energy-minimized in program 
O. (b)Western blot analysis of the expression levels of CSP-3 in two Pdpy-30csp-3 transgenic lines and two 
Pdpy-30csp-3(F57D) transgenic lines in the csp-3(tm2260); ced-5(n1812) mutant background.  The CstF-64 
protein was used as a loading control. 
 
 
 
CSP-3 inhibits auto-activation of the CED-3 zymogen  
The association of CSP-3 with CED-3 may interfere with either the activation of the 
CED-3 zymogen or the activity of the activated CED-3 protease or both.  I first tested whether 
CSP-3 may block the auto-activation of the CED-3 zymogen using an in vitro assay described 
previously(20).  In this assay, the CED-3 zymogen synthesized in the rabbit reticulocyte lysate 
first existed as an unprocessed precursor and then was slowly auto-processed into active forms 
(Fig. 2.6a, lanes 1–3).  The auto-activation of the CED-3 zymogen was inhibited by the addition 
of the GST-CSP-3 protein (Fig. 2.6a, lanes 4–6) but not affected by addition of a similar amount 
of the GST-CSP-3(F57D) or GST protein (Fig. 2.6a, lanes 1-3, 7-9). 
 
  
Figure 2.6  CSP-3 specifically inhibits the auto-activation of the CED-3 zymogen.  (a) CSP-3 inhibits auto-
activation of the CED-3 zymogen. GST (93 nM, lanes 1-3), GST-CSP-3 (12 nM, lanes 4-6), or GST-CSP-3(F57D) 
(12 nM, lanes 7-9) was incubated with 35S-Methionine labeled CED-3 zymogen as described in METHODS.  At 
different time points (30, 90, and 150 min), an aliquot of the reaction was taken out and SDS sampling buffer was 
 24 
added to stop the reaction.  The samples were resolved by 15% SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and subjected to autoradiography.  (b) CSP-3 delays but does not block CED-4-mediated activation of CED-
3. GST (93 nM) or GST-CSP-3 (12 nM) was incubated with 35S-Methionine labeled CED-3 zymogen in the absence 
or presence of oligomeric CED-4 (40 nM) (added 20 min later).  At 30, 80, 130, 180, and 230 min, an aliquot of the 
reaction was taken out and SDS sampling buffer was added.  One half of the aliquot was resolved by 15% SDS-
PAGE and subjected to autoradiography (upper panel).  One fourth of the aliquot was used for the immunoblotting 
analysis using an anti-GST antibody (bottom panel). (c) Oligomeric CED-4 overrides CSP-3 inhibition to induce 
CED-3 activation.  Preformed GST-CSP-3/CED-3-Flag complexes (~70 nM of CED-3-Flag) were incubated either 
with CED-3 buffer or with increasing concentrations of oligomeric or monomeric CED-4 at 30°C for 30 min (see 
METHODS), before they were resolved on 15% SDS-PAGE and detected with an anti-Flag antibody. (d) CSP-3 
does not inhibit the activity of the active CED-3 protease in vitro.  CED-3-Flag was co-expressed with GST, GST-
CSP-3, or GST-CSP-3(F57D) for 3 h in bacteria.  The bacterial lysate containing similar levels of active CED-3 
(acCED-3) and GST fusion proteins (Fig. 2.7b) was incubated with 35S-Methionine-labeled CED-9 for 2 h at 30°C.  
In one reaction, the caspase inhibitor, iodoacetic acid (5 mM), was included.  The reactions were resolved by 15% 
SDS-PAGE and detected by autoradiography. (e) A CSP-3 working model in C. elegans.  CSP-3 associates with the 
CED-3 zymogen in all cells.  In cells that normally live, CSP-3 prevents the CED-3 zymogen from dimerization and 
inadvertent auto-activation.  In cells that are programmed to die, CED-4 oligomer overrides CSP-3 inhibition to 
induce the activation of the CED-3 zymogen via the proximity-induced dimerization model6.   
 
 
 
I next examined whether CSP-3 may inhibit the activation of the CED-3 zymogen 
mediated by oligomeric CED-4 (Fig. 2.6b)(20). Oligomeric CED-4 accelerated CED-3 
maturation (Fig. 2.6b, lanes 6-10), leading to the activation of CED-3 at the 30-min time point 
when there was no sign of CED-3 auto-activation (compared lane 1 and lane 6 in Fig. 2.6b).  
Although GST-CSP-3 completely inhibited CED-3 auto-activation (Fig. 2.6b, lanes 11-15), it 
delayed but did not block the activation of CED-3 induced by oligomeric CED-4 (Fig. 2.4b, 
lanes 16-20), as by the 180-min or 230-min time point (lanes 19 and 20) CED-3 was activated to 
the same extent as that seen in CED-3 auto-activation at the 180-min or 230-min time point 
(lanes 4 and 5) or that seen in CED-4-mediated CED-3 activation at the 80-min or later time 
points (lanes 7-10).  I confirmed this observation by adding oligomeric CED-4 to a preformed 
GST-CSP-3/CED-3 zymogen complex and found that oligomeric CED-4, but not the non-
apoptotic CED-4 monomer(20), induced the proteolytic activation of the CED-3 zymogen (Fig. 
2.4c).  These results suggest that CSP-3 inhibits the auto-activation of CED-3 but is unable to 
block CED-4-mediated CED-3 activation, which are consistent with the observations that CSP-3 
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protects cells that normally live but fails to block the death of cells that are programmed to die 
where oligomeric CED-4 is formed. 
 
On the other hand, when GST-CSP-3 was co-expressed with the CED-3 zymogen during 
the CED-3 activation process or incubated with the activated CED-3 protease (acCED-3), it 
failed to inhibit the cleavage of CED-9, an endogenous CED-3 substrate(59), by acCED-3 (Fig. 
2.6d and Fig. 2.7).  This result suggests that once the active CED-3 heterodimeric complex is 
formed, acCED-3 is resistant to the inhibition of CSP-3. 
 
 
Figure 2.7  CSP-3 does not inhibit the protease activity of the activated CED-3.  (a) 5 ng of active 
CED-3 (acCED-3) were incubated with 35S-Methionine-labeled CED-9 and the recombinant proteins 
(250 ng each) or the caspase inhibitor, iodoacetic acid (5 mM) for 2 h at 30°C.  The samples were 
resolved by 15% SDS-PAGE and subjected to autoradiography.  (b) Western blot analysis of the 
expression levels of acCED-3-FLAG and GST fusion proteins in the cell lysates used in Figure 2.6d. 
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DISCUSSION 
In this study, I show that loss of csp-3 in C. elegans causes ectopic deaths of cells that 
normally live, indicating that csp-3 acts as a cell death inhibitor to protect cells from apoptosis. 
CSP-3 shares sequence similarity to the small subunit of CED-3 and can associate with the CED-
3 zymogen through its large subunit.  In vitro CSP-3 inhibits the auto-activation of the CED-3 
zymogen but does not block CED-4-mediated CED-3 activation or the catalytic activity of the 
activated CED-3 caspase. A mutation in CSP-3 (F57D) that weakens the binding of CSP-3 to 
CED-3 markedly reduces its ability to inhibit the auto-activation of the CED-3 zymogen in vitro 
and to protect against cell death in C. elegans.  Altogether, these findings suggest that CSP-3 is a 
protein inhibitor of the C. elegans CED-3 caspase and specifically suppresses the auto-activation 
of the CED-3 zymogen. 
 
Our results are consistent with a model in which CSP-3 binds to the CED-3 zymogen and 
prevents inadvertent CED-3 auto-activation through homodimerization in cells that normally live 
(Fig. 2.6e).  In cells that are programmed to die, EGL-1 binds to the cell death inhibitor CED-9 
and triggers CED-4 disassociation and oligomerization(4, 20). Oligomeric CED-4 then overrides 
CSP-3 inhibition by forcing the dimerization or oligomerization of the CED-3 zymogen and 
subsequent CED-3 proteolytic activation (Fig. 2.6e)(4, 9, 20), as oligomeric CED-4, but not 
monomeric CED-4, is sufficient to induce CED-3 activation from a purified CSP-3/CED-3 
zymogen inhibitory complex in vitro (Fig. 2.6c).  Oligomeric CED-4 may achieve this by 
binding to the CED-3 zymogen and inducing a CED-3 conformational change that weakens 
CED-3 binding to CSP-3.  Alternatively, CED-4 may compete with CSP-3 for binding to the 
CED-3 zymogen.  In either case, CSP-3 can delay CED-4-mediated activation of CED-3 in vitro 
(Fig. 2.6b), causing mild inhibition of programmed cell death in vivo when overexpressed (Fig. 
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2.2f).  Using this unique mechanism, CSP-3 is able to safeguard against inadvertent CED-3 auto-
activation in cells that normally live, and at the same time, does not interfere with normal 
programmed cell death (Fig. 2.6e). 
 
Given the importance of caspases in cell killing and the presence of caspase inhibitors in 
both mammals and fruit flies such as the IAP family of apoptosis inhibitors that play crucial roles 
in regulating apoptosis activation(22, 28), it is surprising that no direct caspase inhibitor had 
been identified previously in C. elegans and it was unclear how the activity of CED-3 is tightly 
controlled in cells that normally live.  The identification of CSP-3 as a novel CED-3 inhibitor 
provides an answer to this enigma.  However, given the relatively weak phenotype of the csp-3 
mutant animals and the presence of multiple IAP proteins in mammals and fruit flies(23-27), it is 
possible that additional cell death or caspase inhibitors exist and act redundantly with CSP-3 and 
CED-9 to safeguard the survival of cells that should live in C. elegans.   
 
Our study also reveals a previously unreported mechanism by which caspase activation 
can be regulated in general.  I suggest that there are CSP-3-like partial caspase homologues in 
mammals that negatively regulate the activation of caspases by forming inactive heterodimers 
with functional caspases.  These CSP-3-like caspase inhibitors may thus act redundantly with 
IAP proteins to inhibit apoptosis(60).  The CSP-3-like proteins could also arise from alternative 
splicing of the functional caspase genes, as in the case of the caspase-2 gene, which encodes two 
alternatively spliced products, a long form (caspase-2L) and a short form (caspase-2S)(61).  
Caspase-2S contains only the pro-domain and the large subunit of caspase-2L.  When caspase-2S 
is overexpressed in Rat-1 cells, it inhibits apoptosis induced by serum deprivation(61).  It is 
conceivable that caspase-2S may do so by binding to the small subunit of the caspase-2 zymogen 
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or similar regions of other initiator caspases through its large subunit and forming inactive 
heterodimers.  Alternatively, caspase-2S may compete with the caspase-2 zymogen for binding 
to the caspase-2 activator.  In either case, caspase-2S can block homodimerization of the 
caspase-2 zymogen needed for its activation but is unlikely to affect the activity of the activated 
caspase. 
 
METHODS 
Strains.  I cultured strains of C. elegans at 20°C using standard procedures(62), unless otherwise 
noticed.   The N2 Bristol strain was used as the wild-type strain.  Most of the alleles used in this 
study have been described previously(1), except csp-3(tm2260), csp-3(tm2486), inIs179, 
smIs179, and bzIs8.  bzIs8 is an integrated transgene located on LG X and contains a Pmec-4gfp 
construct(54), which directs GFP expression in six C. elegans touch receptor neurons.  inIs179 is 
an integrated transgenic array located on LG II and contains a Pida-1::gfp construct(55), which 
directs GFP expression in the phasmid neurons (PHA, PHB and PHC), ventral cord neurons 
(VC), hermaphrodite-specific neurons (HSN), and ADE neurons.  
 
Isolation of csp-3(tm2260) and csp-3(tm2486) deletion alleles.  I isolated the csp-3(tm2260) 
and csp-3(tm2486) deletion alleles from TMP/UV mutagenized worms(63).  Nested primers used 
to screen for the csp-3(tm2260) and csp-3(tm2486) alleles by PCR were 5’ 
CGCCTCAAACGCCACTGGAT 3’ and 5’ GCTAGCATGACATCGTCACA  3’ for the first 
round amplification and 5’ ATTCATCGTAGCAGCGGGAA’ and 5’ 
CGCCACTGGATTCTCTGGTA 3’ for the second round. Both mutants were backcrossed with 
wild-type (N2) animals at least six times before they were analyzed further. 
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Counting of cells in the anterior pharynx and apoptotic cell corpses.  I scored nuclei in the 
anterior pharynx of L4 larvae and cell corpses in animals at various embryonic and larval stages 
using Nomarski optics as previously described(64). 
 
Quantification of cells labeled with GFP.  I counted cells derived from a variety of lineages 
with the aid of integrated transgenes that express GFP in various different cell types.  L4 larval 
animals were scored for missing cells using Nomarski optics equipped with epifluorescence. 
 
Assays for embryonic lethality and other developmental abnormalities.  I transferred 
hermaphrodite animals to fresh plates every 12 h and counted the number of eggs that they laid 
and the number of embryos that hatched as described previously(56).  Animals were also scored 
for uncoordinated body movement (Unc). 
 
Molecular biology.  Standard methods of cloning, sequencing, and polymerase chain reaction 
amplification (PCR) were used.  I generated the Pcsp-3csp-3::gfp fusion construct by inserting a 
csp-3 minigene containing 4200 bp of the csp-3 promoter and the full-length csp-3 cDNA into 
the pPD95.77 vector.  I obtained the full-length csp-3 cDNA using reverse transcription PCR 
(RT-PCR).  The csp-3 cDNA clone containing the F57D substitution was generated using a 
QuikChange Site-Directed Mutagenesis kit (Stratagene Inc., La Jolla, CA, USA) and confirmed 
by DNA sequencing. 
 
Transgenic animals.  I performed germline transformation as described previously41. The Psur-
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5csp-3, Pdpy-30csp-3, Pdpy-30csp-3(F57D), or csp-3(+) construct (at 25 ng µl–1 each) was injected into 
animals with the appropriate genetic background using Psur-5::gfp (25 ng µl–1) as a co-injection 
marker, which directs GFP expression in all somatic cells18. The Pcsp-3csp-3::gfp translational 
fusion construct (25 ng µl–1) was injected into csp-3(tm2260); ced-5(n1812) animals with pRF4 
(50 ng µl–1), a dominant rol-6 construct as a co-injection marker. 
 
Expression and purification of the CSP-3 and CED-3 Proteins.   I generated all protein 
expression constructs using the standard PCR-based cloning strategy and verified the clones 
through sequencing.  CSP-3 and CED-3 proteins were expressed either individually or together 
in Escherichia coli strain BL21(DE3) as a N-terminally GST fusion protein and a C-terminally 
Flag-tagged protein using a pGEX-4T-2 vector (Pharmacia) and a pET-3a vector (Novagen), 
respectively.  The soluble fraction of the E. coli lysate expressing GST-CSP-3 proteins (wild-
type or F57D) was purified using a Glutathione Sepharose column and eluted with 10 mM 
reduced glutathione (Amersham). 
 
GST fusion protein pull-down assays.  The GST-CSP-3 fusion protein (wild-type or F57D) or 
GST was co-expressed with CED-3-Flag, CED-3p13-Flag, or Flag-CED-3p17 in BL21(DE3). 
Bacteria were lysed by sonication in the lysis buffer (50 mM Tris at pH 8.0, 0.5 mM EDTA, 
150mM NaCl, 0.01% (v/v) Triton X-100, and 0.5 mM sucrose) with protease inhibitors and the 
soluble fraction was incubated with Glutathione Sepharose beads at 4°C for 2 h.  The Sepharose 
beads were then washed five times with the same buffer before the proteins were resolved on a 
15% SDS polyacrylamide gel, transferred to a PVDF membrane, and detected by 
immunoblotting with an anti-Flag antibody (Sigma).  For CED-4-mediated CED-3 activation 
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assay, the Sepharose beads tethered with GST-CSP-3/CED-3-Flag complexes were washed with 
CED-3 buffer (100 mM Tris at pH 8.0, 250 mM NaCl, 0.1% (v/v) NP-40, 5 mM DTT, 0.5 mM 
sucrose, and 10% (v/v) glycerol) and then incubated with increasing concentrations of 
oliogomeric or monomeric CED-4, prepared as described previously(20), at 30°C for 30 minutes 
with occasional shaking, before they were resolved on 15% SDS-PAGE and detected by 
immunoblotting with an anti-Flag antibody.  To measure the concentration of the CED-3 
zymogen in the pull-down samples, GST fusion pull-down samples were resolved on the SDS 
polyacrylamide gel together with a series of BSA proteins with increasing concentrations.  The 
gel was then stained with Coomassie Blue and the concentration of the CED-3 zymogen was 
estimated by comparing the intensity of the CED-3 band with that of various BSA bands with 
different concentrations. 
 
In vitro CED-3 zymogen activation assay.  The CED-3 zymogen was first synthesized and 
labeled with 35S-Methionine in the TNT Transcription/Translation coupled system (Promega) at 
30°C as described previously(20), in the presence of equal amount of GST-CSP-3, GST-CSP-
3(F57D), or GST.  An aliquot of the reaction was taken out at different time points and mixed 
with SDS sampling buffer to stop the reaction.  For CED-4-mediated CED-3 activation assay, 
oligomeric CED-4 was added 20 minutes after the initiation of the translation reaction.  An 
aliquot of the reaction was then taken out at different time points and mixed with SDS sampling 
buffer to stop the reaction.  All samples were resolved by 15% SDS–polyacrylamide gel 
electrophoresis (SDS–PAGE) and analyzed by autoradiography.  
 
In vitro CED-3 activity assays.  CED-9 was synthesized and labeled with 35S-Methionine in the 
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TNT Transcription/Translation coupled system (Promega) and used as a CED-3 substrate for in 
vitro CED-3 protease activity assays.  The CED-3 zymogen was co-expressed with GST-CSP-3, 
GST-CSP-3(F57D), or GST for 3 h in bacteria.  The bacterial lysate containing similar amounts 
of active CED-3 (acCED-3) and GST fusion proteins was incubated with 35S-Methionine-labeled 
CED-9 for 2 h at 30°C as described previously(65).  The reactions were then resolved by 15% 
SDS–PAGE and analyzed by autoradiography.  
 
In vivo co-immunoprecipitation assay.  I cultured C. elegans animals carrying the integrated 
transgene smIs10 (Pced-3ced-3::gfp) or smIs54 (Pceh-30ceh-30::gfp) in liquid medium for 48 h.  The 
animals were harvested and washed three times with 100 mM KCl.  Bacterial and fungi were 
removed by sucrose gradient centrifugation. The animals were then lysed by sonication in the 
lysis buffer (20 mM HEPES, 100 mM KCl, 0.5% (v/v) NP-40, 1 mM EDTA, and 1 mM DTT) 
with protease inhibitors and the soluble fraction was pre-cleared with Protein-G Sepharose beads 
(Pharmarcia).  Subsequently, the pre-cleared worm lysate was incubated at 4°C with a 
monoclonal anti-GFP antibody (3E6, Qbiogene. Inc) for 1 h with gentle shaking.  Protein-
G Sepharose beads were then added and incubation was continued for 2 more hours. The resins 
were then washed five times with the lysis buffer before the proteins were resolved on a 15% 
SDS polyacrylamide gel, transferred to a PVDF membrane, and detected by immuno-blot using 
an anti-CSP-3 antibody.  
 
Generation and purification of anti-CSP-3 antibodies.  I purified recombinant GST-CSP-3 
protein from the soluble fraction of the bacterial lysate using Glutathione Sepharose™4B beads 
(GE Healthcare) as described above and used it to raise polyclonal antibodies against CSP-3 in 
 33 
rats (Spring Valley Laboratories, Inc.).  2 ml of terminal bleed were then affinity purified using 
nitrocellulose membrane strips carrying 1 mg of CSP-3-His6 protein as described in detail 
previously(65) 
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CHAPTER III 
C. elegans caspase homolog CSP-2 inhibits CED-3 autoactivation and apoptosis in germ 
cells 
 
 
ABSTRACT 
In C. elegans, apoptosis in germ cells is mediated by the same core apoptotic machinery 
that controls apoptosis in somatic cells.  These include the CED-3 caspase, the CED-3 activator 
CED-4, and the cell death inhibitor CED-9. However, germline apoptosis also differs from 
somatic apoptosis in its regulation. I found that CSP-3, a caspase homolog that blocks CED-3 
autoactivation and apoptosis in somatic cells, does not affect apoptosis in germ cells.  
Interestingly, the second C. elegans caspase homolog CSP-2 shares sequence similarity to both 
catalytic subunits of the CED-3 caspase, and surprisingly, contains a stretch of sequence that is 
almost identical to that of CSP-3. Unlike CSP-3 that acts specifically in somatic cells, loss of 
CSP-2 causes increased apoptosis only in germ cells, suggesting that CSP-2 is a germ cell 
specific apoptosis inhibitor.  Moreover, like CSP-3, CSP-2 associates with the CED-3 zymogen 
and inhibits its autoactivation, but does not inhibit CED-4-induced CED-3 activation or the 
activity of the activated CED-3 protease. Thus, two different C. elegans caspase homologs 
employ the same mechanism to prevent caspase autoactivation and apoptosis in different tissues, 
suggesting that this could be a generally applicable strategy for regulating caspase activation and 
apoptosis. 
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INTRODUCTION  
 In Caenorhabditis elegans, many early developing germ cells undergo apoptosis during 
normal oogenesis; this process is called germline apoptosis(31, 32). Germline apoptosis appears 
to be an integral component of the oogenesis program and has been suggested to be important for 
eliminating excess germ cells that acted as nurse cells to provide cytoplasmic components to 
maturing oocytes(31-33). Germline apoptosis is conserved among eukaryotes, from C. elegans to 
humans. Therefore, C. elegans provides an excellent model system for studying the regulation of 
germ cell apoptosis. 
The molecular machinery that mediates germline apoptosis has been extensively studied 
and found to share key components with that of somatic apoptosis.  In particular, CED-3, CED-4 
and CED-9 are essential for apoptosis in both germ cells and somatic cells(31, 32). However, 
regulation of apoptosis in germ cells and in somatic cells appears to differ significantly.  For 
example, the pro-apoptotic BH3 only protein EGL-1 is crucial for somatic apoptosis but is 
dispensable for physiological germ cell death(31). Moreover, C. elegans somatic cells are 
resistant to genotoxic insults, whereas germ cells readily respond to genotoxic stresses to 
undergo apoptosis(34), suggesting that the regulation of germ cell death could be fundamentally 
different from that of somatic cell death. 
One crucial aspect of apoptosis regulation is the regulation of caspases, the aspartate-
specific cysteine proteases that execute the cell killing process(9, 10).  Numerous caspase 
inhibitors have been identified and shown to inhibit the activation or the activities of caspases. In 
particular, the inhibitor of apoptosis proteins (IAPs), characterized by at least one baculoviral 
IAP repeat (BIR) and a RING finger motif(22), are conserved caspase inhibitors in Drosophila 
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and higher organisms(23-27).  However, no IAP homolog has been identified in C. elegans.  
Instead, a partial caspase homolog CSP-3 was found to protect C. elegans somatic cells from 
apoptosis by associating with the CED-3 zymogen and inhibiting CED-3 autoactivation(66). It is 
unclear whether CSP-3 also inhibits CED-3 autoactivation in C. elegans germ cells and how the 
activity of CED-3 is negatively regulated in the germline.   
In this study, I found that a second C. elegans caspase homolog CSP-2, which shares 
sequence similarity to both catalytic subunits of CED-3 (Fig 3.1a), is expressed specifically in 
the C. elegans germline and acts as a germ-cell-specific cell death inhibitor.  Moreover, CSP-2 
associates with the CED-3 zymogen and specifically inhibits CED-3 autoactivation, but not 
CED-3 activation mediated by CED-4 or CED-3’s catalytic activity.  Our findings suggest that 
caspase homologs lacking protease activities serve as dedicated caspase inhibitors in C. elegans 
to prevent CED-3 from inadvertent autoactivation and cells from apoptosis. 
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Figure 3.1. CSP-2, a CED-3 homologue, is expressed specifically in hermaphrodite germ cells. (a) Sequence 
alignment of CED-3, CSP-2B, and CSP-3. Residues that are identical are shaded in yellow and residues that are 
similar in pink. Trp131, Leu132, and Phe 186 of CSP-2B are indicated with red arrowheads.  Underlines delineate 
the large and small subunits of CED-3, respectively. The box indicates the active-site pentapeptide of CED-3. (b) 
The csp-2 gene structure and deletion mutations.  Exons are depicted as boxes and introns as lines.  The translated 
regions of csp-2 are highlighted in blue. Three red boxes indicate the regions of csp-2 removed by the three csp-2 
deletions, respectively. SL1 stands for SL1 trans-spliced leader sequence. (c) RT-PCR analysis of the relative 
abundance of CSP-2A and CSP-2B transcripts. Reverse transcription was performed on poly(A)n mRNA isolated 
from mix-stage wild-type animals, followed by PCR amplification with primers specific to the CSP-2A coding 
region (PCR1 in b), or primers in the CSP-2A/2B coding region (PCR2 in b), or primers specific for a control gene 
rpl-26 (encoding a large ribosomal subunit L26 protein). In the PCR1 lane, the predicted 706-bp CSP-2A-specific 
RT-PCR product was not seen.  In the PCR2 lane, amplification of the 622-bp product corresponding to the CSP-
2A/2B transcript was detected. (d) Western blot analysis of Pcsp-2csp-2::3xFlag transgenic animals.  25 Pcsp-2csp-
2::3xFlag transgenic hermaphrodites or males were solubilized in SDS sampling buffer and resolved on 15% SDS 
polyarylamide gel. The CstF-64 protein was used as a loading control. (e) csp-2 is specifically expressed in C. 
elegans germ cells. Differential interference contrast (DIC) and anti-GFP immuno-staining images of exposed 
gonads of wild type (N2) and smIs372 (Pcsp-2csp-2::gfp) hermaphrodite animals are shown. 
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RESULTS 
Loss of csp-2 causes increased germ cell death but does not affect somatic cell death.   
CSP-2 was first identified as a caspase homolog that shares sequence similarity to both 
catalytic subunits of CED-3 (Fig 3.1a).  However, CSP-2 does not appear to contain a caspase 
activity in vitro(50), probably because it lacks the invariant active-site pentapeptide QACXG (X 
could be R, Q, or G) found in all active caspases (VCCRG in CSP-2)(67).  Interestingly, the 
carboxyl terminal region of CSP-2 is homologous to the small subunit of CED-3 and shares 92% 
identity to CSP-3 (Fig 3.1a), raising an intriguing possibility that CSP-2 may act as a caspase 
inhibitor like CSP-3.  To examine the function of csp-2 in C. elegans, I obtained three different 
csp-2 deletion alleles (Fig. 3.1b).  Two deletions, tm2858 and tm3077, remove parts of the 
carboxyl terminal region of CSP-2, which is present in both csp-2 transcripts identified 
previously (Fig. 3.1b)(50). These two csp-2 transcripts conceptually encode two proteins, CSP-
2A and CSP-2B, respectively. CSP-2B is identical to the carboxyl terminus of CSP-2A, which 
has an extra 563 amino acid at the amino terminus. Since CSP-2B transcript is trans-spliced to 
the SL1 spliced leader, it is an independent, complete transcript(50, 68). Indeed, RT-PCR 
analysis of mixed stage wild-type animals reveals that CSP-2B is the dominant csp-2 message 
and I barely detected any CSP-2A transcript (Fig. 3.1c).  Moreover, in western blot analysis, I 
only detected a protein of approximately 33 kDa, the size of CSP-2B, in worm lysate derived 
from animals carrying a complex transgene array expressing CSP-2::3xFlag under the control of 
its own promoter (Pcsp-2csp-2::3xFlag; Fig. 3.1b and 3.1d).  These results indicate that CSP-2B is 
the major CSP-2 protein expressed in C. elegans, although very low-level expression of CSP-2A 
cannot be ruled out.  The third deletion, ok1742, specifically removes a region in CSP-2A but 
does not affect the CSP-2B coding region.  
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To investigate whether csp-2 affects apoptosis, I counted the number of apoptotic cells in 
the germline and embryos of csp-2 deletion mutants, two developmental stages with active 
apoptosis events. Since apoptotic cells are swiftly engulfed in C. elegans, I sensitized these cell 
corpse assays by counting ced-6(n2095); csp-2 and ced-2(n1994) csp-2 double mutants, in which 
cell corpse engulfment is disabled due to the inactivation of the ced-2 or the ced-6 gene and a 
small increase in cell death will result in a greater increase in the number of persistent cell 
corpses(66, 69). Unlike the csp-3(tm2260) mutation that causes increased cell deaths in C. 
elegans embryos and ectopic deaths of neurons that normally live(66), csp-2(tm2858) and csp-
2(tm3077) do not seem to affect embryonic cell deaths (Fig. 3.2a and b) or result in missing 
touch cells in larvae (Fig. 3.2c; data not shown), suggesting that csp-2 does not affect apoptosis 
in somatic tissues. However, I did observe a slight increase in germ cell deaths in csp-2(tm2858) 
and csp-2(tm3077) animals compared with wild-type animals (Fig. 3a; data not shown) and the 
increase in germ cell corpses is easily detected in the ced-6(n2095) and ced-2(n1994) mutant 
backgrounds (Fig. 3.3b to e), suggesting that loss of csp-2 causes increased germ cell deaths and 
that CSP-2 inhibits apoptosis in germ cells.  By contrast, I did not observe increased germ cell 
corpses in csp-3(tm2260), csp-3(tm2260); ced-6(n2095), or csp-3(tm2260); ced-2(n1994) 
animals, compared with wild-type, ced-6(n2095), and ced-2(n1994) animals, respectively (Fig. 
3.3a, c and e).  Nor did I observe further increase in germ cell deaths in the csp-3(tm2260); csp-
2(tm3077) double mutant or in the csp-3(tm2260); ced-6(n2095); csp-2(tm3077) and csp-
3(tm2260); ced-2(n1994) csp-2(tm3077) triple mutants (Fig. 3.3a, c, and e), indicating that csp-3 
does not contribute to the inhibition of germ cell death.  Interestingly, unlike csp-2(tm2858) and 
csp-2(tm3077) deletion mutations, csp-2(ok1742), which removes only the CSP-2A coding 
region, did not seem to affect germ cell death (Fig. 3.3c).  This result is consistent with our 
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observations that the CSP-2B transcript is the dominant csp-2 transcript in C. elegans and 
suggests that CSP-2B is mainly responsible for inhibiting germ cell death in the csp-2 locus and 
that CSP-2A is not critical for this inhibitory function. I thus only analyzed the activity of CSP-
2B hereafter. 
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Figure 3.2. Inactivation of csp-2 does not affect apoptosis in somatic cells. (a, b) Embryonic cell corpse assays.  
Cell corpses were scored in the indicated strains. The ced-6(n2095) allele was used in b. Bean (B/C), 1.5-fold (1.5), 
2-fold (2), 2.5-fold (2.5), 3-fold (3) and 4-fold (4) stage embryos were scored. The y axis represents the average 
number of cell corpses scored. Error bars are standard errors of mean (s.e.m.)  At least 15 embryos were scored for 
each stage. The significance of differences between different genetic backgrounds was determined by unpaired t 
tests. *, P < 0.05; **, P < 0.0001. (c) Inactivation of csp-2 does not cause ectopic death of touch receptor neurons.  
An integrated transgene (bzIs8) was used to monitor the survival of six touch receptor neurons (green circles) as 
described in Materials and Methods. The percentages of animals missing one or more touch cells are shown.  At 
least 100 animals were scored for each strain. 
 
 
 
 
 
 
Figure 3.3. Loss of csp-2 causes increased apoptosis in germ cells. Germ cell corpses were scored in the indicated 
strains from one gonad arm 48 hours post L4 to adult molt (a, c, e, f and g) or every 12 hours post L4 to adult molt 
(b and d). Average numbers of germ cell corpses are shown. Error bars represent the standard errors of mean 
(s.e.m).  At least 15 animals were scored in each strain or time point. In b, the significance of difference between 
ced-6(n2095) and csp-2(tm3077); ced-6(n2095) animals was determined by two-way analysis of variance 
(ANOVA).  *, P < 0.05 for the whole time course. In c, the significance of differences between various csp; ced-
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6(n2095) strains and the ced-6(n2095) strain was determined by unpaired t tests.  **, P < 0.0001. All other points 
had P values > 0.05. In d, the significance of difference between ced-2(n1994) and ced-2(n1994) csp-2(tm3077) 
animals was determined by two-way ANOVA. **, P < 0.0001 for the whole time course. In e, the significance of 
differences between different csp; ced-2(n1994) strains and the ced-2(n1994) strain was determined by unpaired t 
tests.   **, P < 0.0001. All other points had P values > 0.05. (f, g) Rescue of the csp-2 mutant by Ppie-1gfp::csp-2B, 
Pcsp-2csp-2::gfp, or Phspcsp-2B transgenes. The significance of differences between transgenic strains and the ced-
6(n2095); csp-2(tm3077) strain (f), between transgenic strains and the ced-2(n1994) csp-2(tm3077) strain (g), or 
between the smIs389-containing strains and the ced-2(n1994) strain (g) was determined by unpaired t tests.  **, P < 
0.0001. *, P < 0.01.  All other points had P values > 0.05. (h) The Phspcsp-2B transgenes rescue the missing cell 
defect of the csp-3(tm2260) mutant. The presence of touch cells was scored as described in Fig. 3.2c. 
 
Loss of csp-2 reduces animal brood size.   
I also examined whether ectopic deaths of germ cells in csp-2(lf) mutants affect brood 
size, as has been observed in animals deficient in ced-9, another anti-apoptosis gene(56).  Both 
csp-2 mutants (tm3077 and tm2858) had significantly reduced brood sizes, approximately 60% 
of that observed in wild-type animals (Table 3.1). On the other hand, the csp-2(ok1742) mutant, 
which did not display ectopic germ cell deaths, had a normal brood size (Fig. 3.3c).  Moreover, 
csp-2(tm3077) exacerbated the sterility defect caused by a weak loss-of-function mutation in 
ced-9 (n1653ts)(56), resulting in complete sterility of the ced-9(n1653ts); csp-2(tm3077) double 
mutant (Table 3.1). These results suggest that csp-2 is important for normal germline 
development in C. elegans. 
 
Table 3.1  The csp-2 mutations cause reduced brood size 
Genotype Brood size a 
N2  249 + 28 
csp-2(tm3077)    142 + 31b 
csp-2(tm2858)   155 + 19b 
csp-2(ok1742)   225 + 27 
ced-9(n1653ts)    22 + 11 
ced-9(n1653ts); csp-2(tm3077)     0.0 + 0.4c  
a All strains were maintained at 20°C, except that ced-9(n1653ts) and ced-9(n1653ts); csp-2(tm3077) 
strains were maintained at 25°C.  Brood size was scored as the number of eggs laid by each 
hermaphrodite animal. Data shown are mean + S.D. and are derived from three independent experiments. 
20 animals were scored in each experiment.  
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b Compared with N2 animals, P < 0.0001 (two-tail student t test).  Compared with csp-2(ok1742) animals, 
P < 0.0001(two-tail student t test). 
c Compared with ced-9(n1653ts) animals, P < 0.001(two-tail student t test).   
 
 
CSP-2B is specifically expressed in C. elegans germline.  
I next examined the expression patterns of csp-2 by constructing a CSP-2 translational 
GFP fusion under the control of its own promoter (Pcsp-2csp-2::gfp) and generating a low-copy 
integrated transgene (smIs372) carrying Pcsp-2csp-2::gfp through biolistic bombardment (Fig. 
3.1b)(70). smIs372 fully rescued the increased germ cell corpse phenotype of the ced-2(n1994) 
csp-2(tm3077) mutant (Fig. 3.3g), suggesting that the fusion protein is expressed in the right 
cells and targeted to the appropriate cellular locations. Using an antibody to GFP, I detected 
CSP-2::GFP in the cytoplasm of all germ cells of smIs372 hermaphrodite animals but failed to 
see any GFP staining in somatic cells (Fig. 3.1e and data not shown).  This cytoplasmic staining 
pattern of CSP-2::GFP is similar to that of CSP-3::GFP(66), suggesting that both proteins act in 
cytoplasm to inhibit apoptosis.  Interestingly, in immunoblotting analysis of worm lysate from 
male or hermaphrodite animals carrying the Pcsp-2csp-2::3xFlag complex array, I detected 
expression of CSP-2B only in hermaphrodites but not in males (Fig.. 3.1d).  Since no cell death 
occurs in male germline(31, 32), expression of CSP-2 may be dispensable in males. 
To verify that germline expression of CSP-2B is sufficient to mediate the csp-2 function, 
I expressed a GFP::CSP-2B fusion under the control of the pie-1 promoter (Ppie-1GFP::CSP-2B) 
in complex transgene arrays that allow expression of transgenes in the germline(71). Ppie-
1GFP::CSP-2B fully rescued the increased germ cell corpse phenotype of the ced-6(n2095); csp-
2(tm3077) mutant, whereas a mutant Ppie-1GFP::CSP-2B(W131E, L132R, F186D) construct 
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failed to do so (Fig. 3.3f; see below), confirming that CSP-2B is responsible for the csp-2 
activity in inhibiting germ cell deaths.  I could also rescue the csp-2(lf) defect or even cause mild 
suppression of germ cell deaths by ubiquitously overexpressing CSP-2B under the control of the 
heat-inducible promoter (Phspcsp-2B) from a low-copy transgene (smIs389) generated by biolistic 
bombardment (Fig. 3.3g).  Moreover, the Phspcsp-2B transgenes could rescue the missing cell 
defect of the csp-3(lf) mutant in somatic cells (Fig. 3.3h)(66).  However, like CSP-3(66), 
overexpression of CSP-2B in soma did not obviously suppress the death of somatic cells that are 
programmed to die (data not shown).  These results indicate that csp-2 may use a mechanism like 
that of csp-3 to prevent cell death.  
 
CSP-2B associates with the CED-3 zymogen.   
Because CSP-2B shares sequence similarity to both the large and the small subunits of 
CED-3 that form the active p17/p13 heterodimeric protease complex (Fig. 3.1a)(65), I tested 
whether CSP-2B may associate with CED-3 in vitro like CSP-3(66). Using a glutathione S 
transferase (GST) fusion protein pull-down assay, the CED-3 zymogen tagged with a Flag 
epitode was pulled down by the GST-CSP-2B fusion, when both were co-expressed in bacteria 
(Fig. 3.4a). By contrast, the GST control protein failed to pull down CED-3, suggesting that 
CSP-2 interacts with the CED-3 zymogen.  I then characterized the interaction between CSP-2B 
and different domains of CED-3 and found that the large subunit (p17) and the small subunit 
(p13) of CED-3 each could associate with CSP-2B specifically (Fig. 3.4b).  Therefore, CSP-2B 
may interfere with the function of CED-3 by binding to either region of the CED-3 zymogen. 
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Figure 3.4. CSP-2B associates with CED-3 in vitro. (a) CSP-2B binds to the CED-3 zymogen. GST-CSP-2B, 
GST-CSP-2B(mut), or GST was co-expressed in bacteria with the CED-3 zymogen tagged with a Flag epitode 
(CED-3-Flag). “mut” stands for W131E, L132R, and F186D substitutions. One portion of the soluble fraction was 
used in the western blot analysis to examine the expression levels of GST fusion proteins and CED-3-Flag using 
anti-GST and anti-Flag antibodies, respectively.  The remaining portion of the soluble fraction was used in the GST 
fusion protein pulldown experiment and the amount of CED-3-Flag pulled down was analyzed by the western blot 
analysis using an anti-Flag antibody. (b) CSP-2B associates with both the large subunit and the small subunit of the 
CED-3 zymogen in vitro.  The cartoon shows the domain structure of the CED-3 zymogen, with arrows indicating 
the three proteolytic cleavage sites that lead to the activation of the CED-3 zymogen. The large (p17) and the small 
(p13) subunits of CED-3 are shown below as boxes. The Flag epitode is labeled with green. GST-CSP-2B, GST-
CSP-2B(F186D), GST-CSP-2B(W131E, L132R), GST-CSP-2B(C134E), or GST was co-expressed in bacteria with 
the CED-3 large subunit (Flag-p17) or the small subunit (p13-Flag), both of which are tagged with a Flag epitode. 
One portion of the soluble fraction was used in the western blot analysis to examine the expression levels of GST 
fusion proteins and CED-3 subunits using anti-GST and anti-Flag antibodies, respectively.  The remaining portion 
of the soluble fraction was used in the GST fusion protein pulldown experiments and the amount of CED-3 subunits 
pulled down was analyzed by the western blot analysis using an anti-Flag antibody. (c) Structural model of the 
CED-3/CSP-2B complex. Because all caspases with known structures share a highly conserved core structure, the 
structure of caspase-3 (PDB code 1pau) was used to represent the structures of CED-3 and CSP-2B. The large 
subunit of CED-3 is shown in green, the small subunit shown in lemon. The large subunit of CSP-2B is shown in 
magenta, the small subunit in light pink. 
 
To identify interface residues that are important for CSP-2B binding to CED-3, I 
constructed a three-dimensional structural model of the CED-3/CSP-2 complex based on the 
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crystal structure of active caspase-3 (Fig. 3.4c)(58). I then mutated several potential interface 
residues and examined whether these mutations interfered with the binding of CSP2B to CED-3 
(data not shown). I found that Trp131 and Leu132, two residues in a CSP-2B region homologous 
to the large subunit of CED-3, were required for CSP-2B binding to the small subunit of CED-3 
(Fig. 3.1a and bottom panel of Fig. 3.4b).  On the other hand, Phe186 situated in a CSP-2B 
region homologous to the small subunit of CED-3 was important for CSP-2B binding to the large 
subunit of CED-3 in vitro (Fig. 3.1a and the upper panel of Fig. 3.4b). Moreover, a CSP-2B 
mutant carrying these three amino acid substitutions (W131E, L132R, F186D) did not bind 
CED-3 zymogen (Fig. 3.4a) and failed to rescue the csp-2(tm3077) mutant when expressed under 
the control of the pie-1 promoter [Ppie-1GFP::CSP-2B(W131E, L132R, F186D); Fig. 3.3f].  These 
results suggest that association of CSP-2B with CED-3 is important for CSP-2B to protect germ 
cells from apoptosis. 
 
CSP-2B inhibits specifically autoactivation of the CED-3 zymogen.   
Since CSP-3 inhibits apoptosis by specifically blocking autoactivation of the CED-3 
zymogen, I examined whether CSP-2B has a similar activity using an in vitro CED-3 
autoactivation assay described previously(66). As shown in Fig. 3.5a (lanes 1-3), CED-3 
zymogen synthesized in rabbit reticulocyte lysate and labeled with 35S-Methinione was slowly 
auto-processed into active forms.  The autoactivation of the CED-3 zymogen was inhibited by 
the addition of the GST–CSP-2B protein (Fig. 3.5a, lanes 4–6) but was not affected by the 
addition of a similar amount of the GST–CSP-2B(W131E, L132R, F186D) protein or the GST 
protein (Fig. 3.5a, lanes 1–3 and 7–9).  Addition of oligomeric CED-4 to the reactions expedited 
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the activation of the CED-3 zymogen (compare lanes 1-5 and lanes 6-10 in Fig. 3.5b). Although 
GST-CSP-2B completely inhibited CED-3 autoactivation (Fig. 3.5b, lanes 11-15), it delayed but 
did not block the activation of CED-3 induced by oligomeric CED-4 (Fig. 3.5b, lanes 16-20).  
GST-CSP-2B also failed to inhibit the catalytic activity of the active CED-3 protease (Fig. 3.5c). 
Therefore, CSP-2B acts exactly like CSP-3:  it complexes with the CED-3 zymogen and inhibits 
its autoactivation, but is unable to block CED-4-induced CED-3 activation or the activity of 
active CED-3.  
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Figure 3.5. CSP-2B specifically inhibits the autoactivation of the CED-3 zymogen in vitro. (a) CSP-2B inhibits 
autoactivation of the CED-3 zymogen. GST (93 nM, lanes 1-3), GST-CSP-2B (43 nM, lanes 4-6), or GST-CSP-
2B(mut) (43 nM, lanes 7-9) were incubated with 35S-Methionine labeled CED-3 zymogen as described in 
METHODS.  At different time points (30, 90, and 150 min), an aliquot of the reaction was taken out and SDS 
sampling buffer was added to stop the reaction.  The samples were resolved by 15% SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) and subjected to autoradiography.  (b) CSP-2B delays but does not block CED-4-
mediated activation of CED-3. GST (93 nM) or GST-CSP-2B (43 nM) was incubated with 35S-Methionine labeled 
CED-3 zymogen in the absence or presence of oligomeric CED-4 (40 nM) (added 20 min later).  At 30, 80, 130, 
180, and 230 min, an aliquot of the reaction was taken out and SDS sampling buffer was added.  The samples were 
resolved by 15% SDS-PAGE and subjected to autoradiography. (c) CSP-2B does not inhibit the activity of the 
active CED-3 protease in vitro.  CED-3-Flag was co-expressed with GST or GST-CSP-2B for 3 hours in bacteria.  
The bacterial lysate containing similar levels of active CED-3 (acCED-3) and GST fusion proteins was incubated 
with 35S-Methionine-labeled CED-9 for 2 hours at 30°C.  In lane 4, the caspase inhibitor, iodoacetic acid (5 mM), 
was included.  The reactions were resolved by 15% SDS-PAGE and detected by autoradiography. (d) A working 
model of how CSP-3 (left panel) and CSP-2B (right panel) inhibit CED-3 autoactivation and apoptosis in C. elegans 
somatic and germ cells, respectively. 
 
 
DISCUSSION 
Apoptosis is a common feature of metazoan germline development. A wild-type C. 
elegans hermaphrodite has approximately 2000 germ cells generated during its lifetime and more 
than half of these cells undergo apoptosis in a random fashion(31).  By contrast, somatic cell 
deaths in C. elegans occur strictly based on cell lineage information and are invariant from 
animal to animal(2). As such, these two apoptotic processes likely will be controlled through 
very different regulatory pathways.  Indeed, the cell death initiator EGL-1 that is critical for 
somatic apoptosis is totally dispensable for physiological germ cell death(31) and it is unclear 
how germ cell deaths are initiated. Moreover, in this study, I showed that the CED-3 caspase 
inhibitor CSP-3 does not affect germ cell death (Fig. 3.3c and 3.3e), providing further evidence 
that key regulatory components of germ cell death differ from those of somatic cell death to 
achieve tissue specificity.  This finding also suggests that germ cells might possess an alternative 
CED-3 caspase inhibitor(s) to prevent inappropriate or excessive germ cell deaths. 
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CSP-2 is the second caspase homolog identified in C. elegans and shares sequence 
similarity to both the large and the small subunits of CED-3(50).  However, unlike CSP-1, 
another worm caspase homolog that possesses a caspase activity(50), CSP-2 does not display any 
caspase activity in vitro, which may result from its lack of the invariant pentapeptide found in 
active sites of all active caspases(67). Intriguingly, the carboxyl terminus of CSP-2 is 92% 
identical to CSP-3. Phylogenetic analysis of C. elegans CED-3 and CSP proteins suggests that 
csp-2 and csp-3 may have evolved from a common ancestor (Fig. 3.6). Therefore, CSP-2 may 
behave like CSP-3 in binding to CED-3 and inhibiting CED-3 autoactivation(66).  However, 
inactivation of csp-2 does not appear to affect somatic cell death, nor does it enhance the csp-
3(lf) defect in somatic cells (Fig. 3.2), indicating that csp-2 does not affect apoptosis in somatic 
cells.  On the other hand, inactivation of csp-2 does increase apoptosis in germ cells (Fig. 3.3), 
which is not affected by loss of csp-3, suggesting that CSP-2, but not CSP-3, acts specifically in 
germ cells to inhibit apoptosis. Consistent with these findings, CSP-2 is specifically expressed in 
the C. elegans germline.  Therefore, CSP-2 and CSP-3, two closely related paralogs, somehow 
diverged during evolution to act in germ cells and somatic cells, respectively. This change 
created tissue-specific cell death regulation.  
 
 
Figure 3.6. Phylogenetic tree of C. elegans CED-3, CSP Proteins, and mammalian caspase-3. Sequences of 
three C. elegans CSP proteins, CED-3,  mouse and human caspase-3 are compared using the CLUSTALW program. 
The phylogenetic tree was generated based on the multiple sequence alignment and shown as Phylogram Tree with 
branch length. 
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Given the unique mode by which CSP-3 regulates CED-3 autoactivation and somatic 
apoptosis(66), I tested how CSP-2 inhibits cell death. Our biochemical analysis indicates that 
CSP-2 directly associates with the CED-3 zymogen through both its small and large subunits 
(Fig. 3.4a and b). Three amino acid substitutions in CSP-2 (W131E, L132R, F186D) almost 
completely abolish the binding of CSP-2 to the CED-3 zymogen in vitro (Fig. 3.4a) and the 
apoptosis inhibitory activity of CSP-2 in vivo (Fig.. 3.3f), suggesting that binding of CSP-2 to 
CED-3 is critical for its anti-apoptosis function. Moreover, I found that CSP-2 acts exactly like 
CSP-3 in regulating the activity of CED-3:  it associates with the CED-3 zymogen and inhibits 
its autoactivation, but is unable to block oligomeric CED-4-induced CED-3 activation or inhibit 
the catalytic activity of activated CED-3 protease (Fig. 3.5a-c).  These results establish CSP-2 as 
the second caspase inhibitor in C. elegans that acts specifically to inhibit autoactivation of CED-
3 in germ cells, thereby preventing inappropriate germ cell deaths. 
 
It is interesting that two different caspase homologs employ the same strategy to inhibit 
CED-3 activation and apoptosis in two different tissues, somatic cells and germ cells (Fig. 3.5d). 
The repeated use of this unique strategy to negatively regulate CED-3 caspase activation 
underscores the importance of keeping caspases in check in living cells.  In the absence of other 
obvious caspase inhibitors such as IAPs in C. elegans, such caspase-like inhibitors are important 
players in modulating the level of CED-3 activation and preventing inadvertent CED-3 activation 
in cells that should live, without interfering with normal cell death induced by CED-4 (Fig. 
3.5d), as CSP-2B only delayed but did not block CED-4-induced CED-3 activation (Fig. 3.5b). I 
propose that similar incomplete or inactive caspase homologs exist in other organisms and could 
employ the same mechanism to negatively regulate caspase activation and apoptosis.   
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METHODS 
C. elegans strains. I cultured strains of C. elegans at 20°C using standard protocols(62).  The 
Bristol strain N2 was used as the wild type stain. Most of the alleles including ced-2(n1994) and 
ced-6(n2095) used in this study have been described previously(1), except csp-2(tm3077), csp-
2(tm2858), csp-2(ok1742), and bzIs8. The csp-2(ok1742) mutant was obtained from 
Caenorhabditis Genetics Center (CGC) and described in Wormbase 
(http://www.wormbase.org/). bzIs8 is an integrated transgene located on LG X and contains a 
Pmec-4gfp construct(54), which directs GFP expression in six C. elegans touch receptor neurons. 
All strains were backcrossed with N2 animals 4-10 times prior to analysis. 
 
Quantification of germline apoptosis. I identified and quantified germ cell corpses based on 
their characteristic morphology when viewed with Nomarski optics as previously described(31). 
Germline apoptosis was assessed in staged adult animals. At least 15 animals were scored for 
each time point. Data are reported as mean number of germline cell corpses ± standard error of 
the mean (s.e.m). 
 
Isolation of csp-2(tm3077) and csp-2(tm2858) deletion alleles. I isolated the csp-2(tm3077) and 
csp-2(tm2858) deletion alleles from TMP/UV mutagenized worms(63).  Nested primers used to 
screen for the csp-2(tm3077) and csp-2(tm2858) alleles by PCR were 5’ 
GCCGGGCTATCATAATTAAC 3’ and 5’ ATACTGATCACCGAGGCCAT  3’ for the first 
round amplification and 5’ ACGTTTGGGATATCAGTCGA’ and 5’ 
CACGTCATTTCTAGACGTCG 3’ for the second round amplification. Both mutants were 
backcrossed with wild-type (N2) animals at least 4 times before they were analyzed further. 
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RNA isolation and RT-PCR analysis of csp-2 transcripts. I isolated poly(A)n mRNA from 
mix-stage wild-type hermaphrodite animals treated with TRIzol reagent (Invitrogen). First-strand 
cDNA was reverse-transcribed by using Superscript III kit (Invitrogen). PCR was performed 
using specific primers (csp-2A, 5’ GAGCAGTATAGTGCGTTGAGA-GAG 3’ and 5’ 
CTTCCTCTTCCCTTTCTCTCTGTT 3’; csp-2B, 5’ ACGTTTGGGA-TATCAGTCGA 3’ and 
5’ CTAGACGTCGAAGAATAGTTG 3’), which produce a 706 bp (csp-2A) and a 622 bp (csp-
2B) cDNA fragment, respectively. The PCR products were resolved on a 1.5% agarose gel.  
 
Quantification of somatic apoptotic cell corpses and cells labeled with GFP. I counted cell 
corpses in animals at various embryonic and larval stages using Nomarski optics as previously 
described(66). Also I quantified touch receptor neuron cells in bzIs8 as previously described(66).  
 
Plasmids and transgenic strains. I generated the Pcsp-2csp-2::gfp fusion construct by inserting a 
csp-2 genomic fragment containing 4175 bp sequence upstream of the CSP-2A initiation ATG 
codon and the whole csp-2 coding region into the pPD95.79 vector. The resulting plasmid was 
introduced into ced-1(e1735); unc-119(ed3) by the microparticle bombardment together with a 
marker plasmid MM016B that contains the wild-type unc-119 gene to obtain a low-copy 
integrated array smIs372(70). To examine the expression patterns of CSP-2::GFP, anti-GFP 
immunostaining was carried out on the exposed gonads and embryos of smIs372 animals(72). 
            I also generated the Ppie-1GFP::CSP-2B fusion construct by inserting the full-length csp-
2B cDNA into pTE5 vector (Ppie-1GFP) through SpeI and ApaI site. The Ppie-1GFP::CSP-2B fusion 
construct (wild-type or mutant with W131E, L132R, F186D substitutions) was introduced into 
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the ced-6(n2095); csp-2(tm3077) animals through complex DNA arrays as previously 
described(73) and examined for rescue of increased germ cell death phenotype. 
 
Expression and purification of the CSP-2B and CED-3 proteins. I generated all protein 
expression constructs using the standard PCR-based cloning strategy and verified the clones 
through sequencing.  CSP-2B and CED-3 proteins were expressed either individually or together 
in Escherichia coli strain BL21(DE3) as a N-terminally GST fusion protein and a C-terminally 
Flag-tagged protein using a pET-41b vector and a pET-3a vector (Novagen), respectively.  The 
soluble fraction of the E. coli lysate expressing GST-CSP-2B proteins was purified using a 
Glutathione Sepharose column and eluted with 10 mM reduced glutathione (Amersham). 
 
GST fusion protein pull-down assays.  The GST-CSP-2B fusion protein (wild-type or mutants) 
or GST was co-expressed with CED-3-Flag, CED-3p13-Flag, or Flag-CED-3p17 in BL21(DE3). 
Bacteria were lysed by sonication in the lysis buffer [50 mM Tris at pH 8.0, 0.5 mM EDTA, 
150mM NaCl, 0.01% (v/v) Triton X-100, and 0.5 mM sucrose] with protease inhibitors and the 
soluble fraction was incubated with Glutathione Sepharose beads at 4°C for 2 h.  The Sepharose 
beads were then washed five times with the same buffer before the proteins were resolved on a 
15% SDS polyacrylamide gel (SDS-PAGE), transferred to a PVDF membrane, and detected by 
immunoblotting with an anti-Flag antibody (Sigma).   
 
In vitro CED-3 zymogen activation assay. The CED-3 zymogen was first synthesized and 
labeled with 35S-Methionine in the TNT Transcription/Translation coupled system (Promega) at 
30°C as described previously(20), in the presence of equal amount of GST-CSP-2B, GST-CSP-
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2B(W131E,L132R,F186D), or GST.  An aliquot of the reaction was taken out at different time 
points and mixed with SDS sampling buffer to stop the reaction.  For CED-4-mediated CED-3 
activation assay, oligomeric CED-4 was added 20 minutes after the initiation of the translation 
reaction.  An aliquot of the reaction was then taken out at different time points and mixed with 
SDS sampling buffer to stop the reaction.  All samples were resolved by 15% SDS–PAGE and 
analyzed by autoradiography. 
 
Statistics. I performed all statistical analysis using Prism (GraphPad Software). All error bars 
indicate standard errors of the mean (s.e.m). All t tests are two-tailed unpaired t tests. Time 
courses curves were analyzed by two-way ANOVA. 
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Chapter IV      
Hepatitis B Virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ 
increase and cell death 
 
 
 
ABSTRACT 
HBx is a multi-functional hepatitis B virus (HBV) protein that is crucial for HBV 
infection and pathogenesis and a contributing cause of hepatocyte carcinogenesis.  The host 
targets and mechanisms of action of HBx are poorly characterized.  I show that expression of 
HBx in C. elegans induces both necrotic and apoptotic cell death, mimicking an early event of 
liver infection by HBV.  Genetic and biochemical analyses indicate that HBx interacts directly 
with the Bcl-2 homolog CED-9 through a Bcl-2 homology 3 (BH3)-like motif, and this 
interaction triggers an increase in cytosolic Ca2+ and induction of both apoptosis and necrosis in a 
CED-9-dependent manner.  Moreover, Bcl-2 binds HBx in human hepatic cells and can 
substitute for CED-9 in mediating HBx-induced cell killing in C. elegans, suggesting that CED-9 
and Bcl-2 are conserved cellular targets of HBx.  Thus, C. elegans can serve as an animal model 
for identifying crucial host factors and signaling pathways of HBx and aid in development of 
strategies to treat HBV-induced liver disorders.  
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INTRODUCTION 
HBx, one of the four proteins encoded by the HBV genome (36, 41), is a multi-functional 
protein that controls HBV infection and replication (74-76).  HBx affects multiple cellular events 
in infected cells, including transcription (77-79), signal transduction (80-83), proteasome activity 
(84, 85), cell cycle progression (46, 86, 87), and cell death (43, 44, 88-90). HBx has been shown 
to play an important role in neoplastic transformation of hepatocytes in HBV-infected patients.  
For example, HBx expression is detected in the majority of patients with HBV-related 
hepatocellular carcinoma (HCC) and HBx is the most frequently integrated viral sequence found 
in HCC (91). Moreover, in several studies, high incidences of liver tumors were found in 
transgenic mice expressing only HBx, suggesting a causal relationship between HBx and HCC 
(40, 92-96).  How expression of HBx in the liver leads to development of HCC is not 
understood. Adding to the puzzle, HBx binds a vast number of proteins in various in vitro 
systems, including many factors involved in transcription, components of the proteasome, DNA 
repair proteins, mitochondria-related proteins, and cell cycle regulators such as p53 (38, 39, 41, 
84, 97, 98). Most of these protein interactions have not been confirmed under conditions that 
recapitulate HBV infection in hepatocytes. As a result, the actual cellular targets of HBx remain 
elusive (38, 39, 41). 
 
Many studies have linked HBx expression to the activation of necrosis and apoptosis in 
hepatocytes.  HBx can sensitize liver cells to cell death by various insults, including tumor 
necrosis factor-α (TNF-α) and growth factor deprivation (43, 99). HBx induces mitochondria 
aggregation, loss of mitochondrial membrane potential, and cytochrome c release, indicating that 
HBx may act through mitochondria to induce cell death (44, 98, 100, 101). Apoptosis and 
 57 
necrosis are also early events of liver pathogenesis in HBx transgenic mice and may lead to 
development of liver cirrhosis and HCC (45, 46, 99, 100, 102).  While these reports suggest a 
cell death inducing function for HBx, it is unclear what cellular target(s) HBx interacts with to 
induce cell death and how HBx-induced cell death contributes to the development of HCC.  It 
has been hypothesized that chronic hepatocyte cell death causes repeated local liver regeneration 
and release of inflammatory cytokines that promote compensatory hepatocyte proliferation, 
leading to the acquisition of oncogenic mutations and enhancement of hepatocarcinogenesis (46, 
47, 99). Therefore, identification of cellular targets and pathways that mediate HBx-induced cell 
death is critical for treating HBV-related liver disease.  
 
As one of the key intracellular signaling molecules, Ca2+ appears to be central to multiple 
activities of HBx.  HBx is found to trigger cytosolic Ca2+ increase in hepatic cells, which is 
crucial for HBV DNA replication (74, 103).  HBx-induced elevation of cytosolic Ca2+ is also 
important for HBV core assembly (104), some of the HBx-activated transcriptional events (74, 
105), and activation of several signaling pathways, including JNK and MAPK pathways (106, 
107).  Additionally, HBx has been shown to modulate cell death by altering cytosolic Ca2+ (90). 
The cellular target with which HBx interacts to alter cytosolic Ca2+ is unknown and could be the 
crux of HBx biology and HBV therapy. 
Given the extreme complexity of HBx study in mammals, I used the simple, genetically 
tractable animal model C. elegans to identify HBx targets and signaling pathways.  I have 
identified a human Bcl-2 homolog, CED-9, as the cellular target for HBx to induce cytosolic 
Ca2+ increase and cell killing. 
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RESULTS 
Expression of HBx in C. elegans causes ectopic apoptosis and necrosis.   
To assess the activities of HBx in C. elegans, I induced global expression of HBx under 
the control of the C. elegans heat-shock promoters (PhspHBx).  Expression of HBx in C. elegans 
had deleterious effects, leading to a high percentage of embryonic lethality (Fig. 4.1, a and b).  
Approximately 97% of PhspHBx transgenic embryos did not hatch out and were invariably 
deformed (Fig. 4.1, a and b).  Many contained large vacuoles that resembled those seen in 
necrotic cells (arrowheads in Fig. 4.1a) and also had cells with raised-disc like morphology 
characteristic of apoptotic cells (pink arrows in Fig. 4.1a).  To determine the nature of HBx-
induced cell death, I introduced the PhspHBx transgenes into animals defective in ced-3, which 
encodes a cysteine protease essential for apoptosis (3), or animals defective in mec-6, which is 
important for necrosis (108). A strong loss-of-function (lf) mutation in ced-3 (n2433) or mec-6 
(e1342) partially suppressed embryonic lethality caused by HBx overexpression (Fig. 4.1b), 
indicating that both apoptotic and necrotic cell death contributes to the embryonic lethality of 
HBx transgenic embryos. 
To better analyze the cell-killing activity of HBx, I expressed HBx in six 
mechanosensory neurons (ALML/R, AVM, PVM, PLML/R) under the control of the mec-7 gene 
promoter (Pmec-7HBx)(109).  To aid in identification of these non-essential neurons, I expressed 
GFP under the control of the mec-3 gene promoter (Pmec-3GFP), which drives gene expression in 
six touch cells and four other sensory neurons (PVDL/R and FLPL/R)(110).  An integrated 
transgene (smIs98) containing both Pmec-7HBx and Pmec-3GFP was used to assay killing of touch 
cells by HBx (Fig. 4.1c).  On average, 13-50% of touch cells in smIs98 animals underwent 
ectopic cell death, with the two posterior PLM neurons showing most ectopic deaths (50%; Fig. 
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4.1d).  PLM death was thus used in all subsequent genetic analysis. Some of the dying touch 
cells in smIs98 animals displayed an enlarged vacuolar morphology characteristic of necrotic cell 
corpses (Fig. 4.1f)(111) and some displayed the raised disc-like morphology of apoptotic cell 
corpses (Fig. 4.1g).  Consistently, ectopic cell killing by HBx was partially suppressed by either 
ced-3(n2433) or mec-6(e1342) lf mutations and blocked by loss of both genes (Fig. 4.2a).  These 
results confirm that HBx induces both apoptosis and necrosis in C. elegans. 
 
 
Figure. 4.1  Induction of both apoptosis and necrosis in C. elegans by HBx expression. (a) GFP 
fluorescent and differential interference contrast (DIC) images of embryos transgenic for PhspHBx and Psur-
5SUR-5::GFP before (-HS) and after (+HS) heat-shock treatment.  SUR-5::GFP was seen in nuclei of 
many cells at most developmental stages.  Pink arrows indicate apoptotic cell corpses and white 
arrowheads indicate vacuoles of necrotic nature in a dying embryo. (b) Suppression of HBx-induced 
embryonic lethality by a loss-of-function mutation in ced-3 or mec-6 or a gain-of-function mutation in 
ced-9.  HBx transgenic embryos were heat-shocked at 330C for 1 hour.  Under this heat-shock treatment, 
20% of wild-type C. elegans embryos did not hatch out.  L1 and L2 represent two independent 
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extrachromosomal transgenes that were crossed into different mutant backgrounds.  At least 300 
transgenic embryos were scored for each strain. (c) Schematic presentation of the generation of the 
smIs98 strain. Pmec-3GFP directs GFP expression in ten sensory neurons (indicated by green circles).  Pmec-
7HBx directs HBx expression in six of the ten neurons (ALML/R, AVM, PVM, PLML/R), leading to the 
death of some of these neurons (indicated by “X”). An integrated transgene (smIs98) carrying both Pmec-
3GFP and Pmec-7HBx resulted in loss of touch cells, which is shown in d. (d) Ectopic neuronal death 
caused by expression of HBx in six touch cells. smIs3 is an integrated transgene carrying only Pmec-3GFP 
and was used as a positive control.  The percentage of cells killed by HBx in each neuronal cell type was 
shown.  At least 500 L4 stage larvae were scored in each strain. (e-g) DIC and GFP images of the PLM 
neurons in smIs3 or smIs98 animals. PLM displayed a normal, oval-shape morphology with a long 
anterior process and a short posterior process in a smIs3 animal (e).  In smIs98 animals, dying PLM 
neurons adopted a vacuolar morphology characteristic of necrotic cells (f) or a raised-disc like 
morphology characteristic of apoptotic cells (g).  
 
 
 
Genetic pathways leading to apoptosis and necrosis in C. elegans have been well 
characterized (Fig. 4.2b)(4, 7).  In the apoptotic pathway, four key proteins, EGL-1 (similar to 
human BH3-only pro-apoptotic proteins), CED-9 (human Bcl-2 cell death inhibitor), CED-4 
(human Apaf-1), and CED-3 (human caspases), act sequentially to control activation of apoptosis 
(4).  In the necrotic pathway, several conserved endoplasmic reticulum (ER) proteins involved in 
regulating Ca2+ homeostasis, including two Ca2+-binding proteins, CRT-1 (calrecticulin) and 
CNX-1 (calnexin), and two Ca2+ channels, ITR-1 (inositol triphosphate receptor) and UNC-68 
(uncoordinated, a ryanodine receptor homolog), control release of Ca2+ from ER to cytosol in 
response to various necrotic insults (112). Ca2+ elevation in cytosol then initiates necrosis 
through conserved Ca2+-dependent calpain proteases, CLP-1 (calpain family) and TRA-3 
(transformer), and their downstream aspartyl proteases, ASP-3 and ASP-4 (113).  I examined 
whether these key components of apoptotic and necrotic cell death pathways affect HBx-induced 
cell death.  Loss of egl-1, ced-3 or ced-4 partially suppressed HBx-induced cell death (from 50% 
to 22-26% PLM death; Fig. 4.2a), indicating that HBx induces cell death partly through the 
apoptotic pathway. Likewise, loss of crt-1, cnx-1, itr-1, clp-1, tra-3, asp-3 or asp-4 partially 
suppressed HBx-induced cell death (Fig. 4.2a), indicating that HBx induces cell killing in part 
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through the necrotic pathway. Importantly, loss of ced-3 and one of the components in the 
necrotic pathway (mec-6, clp-1, itr-1, and crt-1) almost completely blocked ectopic touch cell 
death induced by HBx (Fig. 4.2a), indicating that apoptosis and necrosis account for virtually all 
cell death induced by HBx. 
 
Figure 4.2. Molecular components and pathways involved in HBx-induced apoptosis and necrosis in 
C. elegans.  (a) Cell killing activity of HBx in various mutants defective in either apoptosis or necrosis or 
both. The percentage of PLM death was scored in animals with the indicated genotypes.  At least 200 L4 
stage larvae from each strain were scored.  (b) HBx-induced apoptosis and necrosis pathways in C. 
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elegans.  Key regulators of apoptosis and necrosis in C. elegans are shown, with corresponding human 
homologs (apoptosis) and biochemical properties (necrosis) indicated.  [Ca2+]i indicates cytosolic Ca2+ 
concentration.  MPTP and CsA indicate mitochondria permeability transition pore and cyclosporine A, 
respectively.  The position and biochemical function of mec-6 in necrosis are unknown. 
 
 
CED-9 is required for HBx-induced cell death.   
Like loss of egl-1, ced-4 or ced-3, a gain of function (gf) mutation (n1950) in ced-9 
prevents most somatic apoptosis in C. elegans(114). This mutation results in a glycine to 
glutamate substitution at position 169, which is located within the highly conserved BH1 domain 
of CED-9(114). However, unlike egl-1(lf), ced-4(lf) and ced-3(lf) mutations that partially 
blocked HBx-induced cell death, ced-9(n1950gf) completely inhibited HBx-induced touch cell 
death (Fig. 4.2a) and embryonic lethality (Fig 4.1b). Moreover, a strong lf mutation in ced-9 
(n2812) completely suppressed ectopic cell-killing induced by HBx in the ced-4(n1162) mutant 
background (Fig. 4.2a), which allows survival of ced-9(n2812) animals (loss of ced-9 causes 
massive ectopic apoptosis and embryonic lethality)(115).  These results indicate that HBx 
induces both apoptotic and necrotic cell death through CED-9.  
ced-9(n1950gf) results in substitution of Gly169 by Glu, an important residue in the BH3-
binding pocket of CED-9, which disrupts the binding of the BH3-only protein EGL-1 to CED-9 
and prevents EGL-1-induced release of the pro-apoptotic CED-4 dimer from the CED-4/CED-9 
complex tethered on the surface of mitochondria (19, 20, 116).  I hypothesized that HBx acts by 
binding to CED-9, thereby antagonizing its death inhibitory function.  I tested whether HBx 
binds CED-9 in vitro using a glutathione S transferase (GST) fusion protein pull-down assay. 
GST-HBx specifically interacted with CED-9 tagged with a six-histidine epitope but not with the 
mutant CED-9(G169E) protein (Fig. 4.3a).  Interestingly, HBx contains a sequence (residues 
116-132) that is distantly related to the BH3 motif found in many pro-apoptotic BH3-only 
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proteins (Fig. 4.3b)(117, 118).  I tested the possibility that the interaction with CED-9 occurs 
through this motif by altering two amino acids (Gly124 to Leu and Ile127 to Ala) in HBx that are 
conserved among BH3-only proteins and that face CED-9 in a structural model of the HBx/CED-
9 complex (Fig. 4.3b and Fig. 4.4a).  G124L substitution markedly reduced and I127A 
substitution compromised the binding of HBx to CED-9 in vitro (Fig. 4.3c).  Alteration of both 
residues (G124L; I127A) completely abolished association of HBx with CED-9 (Fig. 4.3c).  
When HBx(G124L) or HBx(I127A) was expressed under the control of the mec-7 promoter, both 
mutant proteins displayed reduced cell killing activity, while the double mutant, HBx(G124L; 
I127A), induced minimal ectopic touch cell death (Fig. 4.3d).  Consistently, HBx(G124L; 
I127A) did not result in embryonic lethality in C. elegans like HBx when expressed under the 
control of the heat-shock promoters (Fig. 4.3e).  These in vitro and in vivo results together 
indicate that association of HBx with CED-9 is required for HBx to induce ectopic cell killing in 
C. elegans.  
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Figure 4.3.  Association of HBx with CED-9 or Bcl-2 family proteins through the BH3-like motif of 
HBx. (a) Purified GST-HBx (2.5 µg) immobilized on glutathione resins were incubated with 5 µg of 
CED-9(68-251)-His6 or CED-9(68-251; G169E)-His6. One portion of the incubation mix was analyzed by 
western blot (IB) to examine the input levels of GST-HBx and CED-9(68-251)-His6 proteins. The 
remaining portion was used for the pulldown experiments and the proteins remaining on the resin were 
resolved on a SDS polyacrylamide gel (SDS-PAGE) and visualized by immunoblotting using an antibody 
to the six-histidine epitope.  (b) Sequence alignment of the BH3 domains from various proapoptotic BH3-
only proteins and the BH3-like motif of HBx. Residues that are identical are shaded in red and residues 
similar are labeled with pink.  Gly124 and Ile127 of HBx are indicated with arrows and Glu125 and 
Glu126 are shown with arrowheads.  (c) Purified CED-9(68-251)-His6 (5 µg) were incubated with 2.5 µg 
of GST-HBx, GST-HBx(G124L), GST-HBx(I127A), or GST-HBx(G124L, I127A) immobilized on 
glutathione resins.  The pull-down assay was carried out as described in A.  (d) Cell killing activity of the 
HBx mutants.  bzIs8 is an integrated transgene carrying the Pmec-4GFP construct, which directs GFP 
expression in six touch cells and allows scoring of the PLM cell death caused by wild-type and mutant 
Pmec-7HBx constructs.  L1 and L2 represent two independent extrachromosomal (Ex) transgenic lines.  At 
least 100 transgenic L4 larvae were scored in each strain. (e) Assay of embryonic lethality induced by 
global expression of HBx or HBx(G124L, I127A).  Embryonic lethality assay was carried out as 
described in Fig. 4.1B. 300 transgenic embryos were scored for each strain. (f) Association of HBx with 
human Bcl-2 and Bcl-xL proteins.  The pull-down assay was carried out as described in a using 2.5 µg of 
GST-HBx, GST-HBx(G124L, I127A) and GST immobilized on glutathione resins, respectively.  5 µg of 
recombinant Bcl-2, Bcl-xL, and Bax proteins that were N-terminally tagged with six histidine and without 
their transmembrane domains (ΔTM) were used in the pull-down assay. 
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To characterize further the interaction between HBx and CED-9, I performed structural 
modeling of the HBx/CED-9 complex using the published EGL-1/CED-9 complex structure 
(119), replacing the EGL-1 BH3 helix with the putative BH3 motif of HBx.  In the modeled 
HBx/CED-9 structure, Glu125 and Glu126 of HBx are in the vicinity of the Gly169 residue of CED-9 
(Fig. 4.4b).  The replacement of Gly169 by a bulky, negatively charged Glu in the ced-9(n1950gf) 
mutant is expected to cause a steric clash and/or charge repulsion with either Glu125 or Glu126 or 
both, disrupting the interaction between HBx and CED-9 (Fig. 4.4b).  I thus generated two single 
Glu to Ala substitutions (E125A and E126A) in HBx and tested whether residues with a neutral, 
smaller side chain may alleviate steric clash or charge repulsion and restore binding of HBx to 
CED-9(G169E).  Although neither mutation affected binding of HBx to wild-type CED-9, 
E125A, but not E126A, specifically restored binding of HBx to CED-9(G169E) in vitro (Fig. 
4.4c).  In vivo, both HBx(E125A) and HBx(E126A) caused ectopic touch cell death and a high 
percentage of embryonic lethality in wild-type animals like HBx when expressed under the 
control of the mec-7 and the heat-shock promoters, respectively (Fig. 4.4, d and e).  However, 
only HBx(E125A), but not HBx or HBx(E126A), induced robust cell or embryo killing in ced-
9(n1950) animals in these assays (Fig. 4.4, d and e).  These results correlate with the 
observations that HBx(E125A), but not HBx or HBx(E126A), was capable of binding to CED-
9(G169E) in vitro (Fig. 4.4c).  Taken together, they provide strong evidence that HBx induces 
both apoptotic and necrotic cell deaths in C. elegans by interacting with CED-9 and that CED-9 
is a cellular target of HBx. 
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Figure 4.4. Restoration of HBx binding to CED-9(G169E) and cell killing in ced-9(n1950) animals 
by a designed compensatory mutation in HBx.  (a) Ribbon stereodrawing of a modeled complex 
structure between the BH3-like domain of HBx (residues 120-128, in red) and CED-9 (in green). The 
BH3-like peptide of HBx interacts with CED-9 through the same interface as the BH3 peptide of EGL-1.  
The two conserved residues (Gly124 and Ile127) in HBx facing the interface are shown in yellow. (b) A 
modeled complex structure between the BH3-like domain of HBx (in red) and CED-9(G169E) (in green), 
in which Glu is in place of Gly169 (in blue).  The larger, negatively charged side chain of Glu169 in 
CED-9 may cause steric clash or charge repulsion or both with two residues in HBx in the vicinity, 
Glu125 and Glu126 (in yellow).  (c) Restoration of HBx binding to CED-9(G169E) by Glu125 to Ala 
substitution in HBx. 5µg of CED-9(68−251)-His6 or CED-9(68−251, G169E)-His6 were incubated with 
2.5 µg of GST-HBx, GST-HBx(E125A) or GST-HBx(E126A) immobilized on glutathione resins.  The 
pull-down assay was performed as described in Fig. 4.3a.  (d) Induction of PLM death in ced-9(n1950) 
animals by HBx(E125A). L1 and L2 represent two independent bzIs8 or ced-9(n1950); bzIs8 transgenic 
lines carrying a wild-type or a mutant Pmec-7HBx construct.  At least 100 transgenic L4 larvae from each 
line were scored.  (e) Embryonic lethality caused by global expression of HBx(E125A) in ced-9(n1950) 
animals.  L1 and L2 represent two independent wild-type or ced-9(n1950) transgenic lines carrying wild-
type or mutant PhspHBx constructs. 300 transgenic embryos were scored.  (f) Restoration of HBx cell 
killing in ced-9(n1950) animals by expression of ced-9 or human Bcl-2.  L1 to L3 represent three 
independent ced-9(n1950); smIs98 transgenic lines carrying either Pmec-7CED-9 or Pmec-7hBcl-2.  At least 
100 transgenic L4 larvae from each line were scored.  
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Human Bcl-2 can substitute for CED-9 in mediating HBx-induced cell death.   
The functions of CED-9 and Bcl-2 in cell death regulation are highly conserved, and Bcl-
2 can partially substitute for ced-9 in inhibiting apoptosis in C. elegans (59, 115, 120).  
Therefore, I tested whether HBx binds Bcl-2 family proteins and if Bcl-2 can substitute for CED-
9 in mediating HBx-induced cell killing in C. elegans.  I found that GST-HBx specifically 
interacted with human Bcl-2 and Bcl-xL, both of which are anti-apoptotic, but not with the pro-
apoptotic BAX protein (Fig. 4.3f).  The binding of HBx to Bcl-2 and Bcl-xL was markedly 
reduced by the G124L and I127A mutations in the BH3-like motif of HBx, indicating that HBx 
also interacts with Bcl-2 and Bcl-xL in vitro through the BH3-like motif.   
 
As shown in Fig. 4.2a, HBx was unable to induce touch cell death in ced-9(n1950) 
animals owing to its inability to bind CED-9(G169E). I found that this suppression of HBx-
induced cell death was completely reversed by expression of wild-type CED-9 (Pmec-7CED-9) in 
smIs98; ced-9(n1950) animals (Fig. 4.4f). Importantly, HBx-induced cell killing in smIs98; ced-
9(n1950) animals could also be completely restored by expressing human Bcl-2 under the 
control of the mec-7 promoter (Pmec-7hBcl-2)(Fig. 4.4f).  This finding indicates that HBx likely 
interacts with Bcl-2 and other family members to induce cell killing in humans. 
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Figure. 4.5. Induction of cell death by HBx in human cells through association with human Bcl-2 
proteins. (a) Association of HBx with Bcl-2 and Bcl-xL in HepG2 cells. A co-IP experiment was 
performed in HepG2 cells transfected with pcDNA3.1-Flag-HBx or pcDNA3.1-Flag-HBx(G124L, 
I127A).  The cell lysate was precipitated with an anti-Flag antibody and analyzed by immunoblotting (IB) 
using anti-Flag, anti-Bcl-2, anti-Bcl-xL, and anti-Mcl-1 antibodies, respectively (Lane 3 and 4). One 
portion of the cell lysate was used in immunoblotting analysis to examine the expression levels of HBx 
proteins and Bcl-2 family proteins (Lane 1 and 2). (b, c, d) Analysis of HBx-induced cell killing in 
HepG2 cells by flow cytometry.  HepG2 cells were transfected with 1μg of empty pcDNA3.1 vector (b), 
pcDNA3.1-Flag-HBx (c), or pcDNA3.1-Flag-HBx(G124L, I127A)(d) using pEGFP-C1 (1μg) as a co-
transfection marker.  Only the HBx-transfected cells (GFP positive) are shown. The bottom-left square 
indicates the percentage of living cells, the bottom-right square indicates the percentage of apoptotic cells, 
and top-right square indicates the percentage of necrotic cells.   
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HBx binds Bcl-2 family proteins and induces cell killing in human cells through its BH3-
like motif.   
To test the hypothesis that HBx induces cell death through Bcl-2 family proteins in 
humans, I transiently transfected hepatic HepG2 cells with pcDNA3.1-Flag-HBx or pcDNA3.1-
Flag-HBx(G124L, I127A).  I first examined whether HBx associates with Bcl-2 family proteins 
by co-immunoprecipitation (co-IP) assays. Using an antibody to the Flag epitope, Bcl-2 and Bcl-
xL, but not Mcl-1 (another anti-apoptotic Bcl-2 family member), were co-precipitated with Flag-
HBx from the extracts of transfected HepG2 cells (Fig. 4.5a, Lane 3).  In contrast, no Bcl-xL 
protein and only trace amount of Bcl-2 were co-precipitated with Flag-HBx(G124L, I127A)(Fig. 
4.5a, Lane 4), which was expressed in HepG2 cells at a comparable level to Flag-HBx (Fig. 4.5a, 
Lanes 1 and 2).  These results confirm that HBx physically associates with Bcl-2 and Bcl-xL in 
human cells through its BH3-like motif.  
 
I next studied the cell-killing activity of HBx by staining transfected HepG2 cells with 
both Annexin-V Pacific Blue and propidium iodide (PI).  Flow cytometry analysis indicates that 
there were 10.6% apoptotic cells (Annexin-V positive and PI negative) and 7.92% necrotic cells 
(Annexin-V positive and PI positive) in cells transfected with 1µg of pcDNA3.1-Flag-HBx (Fig. 
4.5c), which were significantly higher than those observed in cells transfected with the same 
amount of pcDNA3.1-Flag-HBx(G124L, I127A)(4.87% apoptotic cells and 1.14% necrotic cells, 
Fig. 4.5d) or empty pcDNA3.1 vector (1.14% apoptotic cells and 0.32% necrotic cells, Fig. 
4.5b).  Therefore, HBx also induced both apoptosis and necrosis in human hepatic cells through 
its BH3-like motif, which is required for HBx association with two host targets and cell death 
inhibitors, Bcl-2 and Bcl-xL (Fig. 4.3f and Fig. 4.5a).  These findings are completely consistent 
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with results obtained in C. elegans studies and validate C. elegans as a useful animal model for 
studying HBx and its cellular targets. 
 
HBx targets CED-9 to induce cytosolic Ca2+ increase.   
Because HBx interacts with CED-9 to induce necrosis and cytosolic Ca2+ increase is 
essential for activation of necrosis in C. elegans (7, 112), I examined whether HBx might target 
CED-9 to affect intracellular Ca2+.   I utilized a C. elegans strain carrying an integrated transgene 
(bzIs17) that expresses a cameleon Ca2+ sensor under the control of the mec-4 gene promoter and 
thus allows monitoring of intracellular Ca2+ in six touch cells through the fluorescence-resonance 
energy transfer (FRET) assay (121, 122).  In this assay, the FRET ratio is indicative of relative 
cytosolic Ca2+ concentration(122).  I first treated bzIs17 animals with thapsigargin, which inhibits 
the ER Ca2+ ATPase that pumps Ca2+ from the cytosol into the ER and is expected to result in 
elevation of cytosolic Ca2+ (112). Indeed, the FRET ratio in the PLM neurons of thapsigargin-
treated animals was significantly higher than that of untreated or vector-treated animals (Fig. 
4.6a).  To better assess the impact of HBx expression on cytosolic Ca2+, I used the asp-3(tm4559) 
mutation to block most of the touch cell deaths (from 50% missing PLMs to 12%, Fig. 4.2a) 
induced by an integrated Pmec-7HBx transgene (smIs451).  Loss of asp-3 on its own did not alter 
cytosolic Ca2+, as the FRET ratios were almost identical between bzIs17 and bzIs17; asp-
3(tm4559) animals (Fig. 4.6b).  However, in bzIs17; asp-3(tm4559); smIs451 animals, I 
observed a 40% increase in the FRET ratio (Fig. 4.6b), indicating that HBx expression in touch 
cells resulted in a significant increase in cytosolic Ca2+.  Importantly, the HBx-induced Ca2+ 
increase was obliterated by the ced-9(n1950) mutation (Fig. 4.6b), which prevents HBx binding 
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to CED-9 (Figs. 4.3 and 4.4).  Therefore, HBx directly targets CED-9 to induce cytosolic Ca2+ 
increase and necrosis in C. elegans.  
 
 
Figure 4.6. CED-9-dependent elevation of cytosolic Ca2+ induced by HBx.  (a) Treatment of bzIs17; 
asp-3(tm4559) animals with 10 μM thapsigargin, an inhibitor of ER Ca2+ reuptake, increased cytosolic 
Ca2+ (indicated by FRET ratio) in PLM neurons.  Untreated or dimethyl sulfoxide (DMSO) treated 
animals were assayed as negative controls. (b) Expression of HBx in touch cells from an integrated Pmec-
7HBx transgene (smIs451) increased the FRET ratio in PLM neurons of bzIs17; asp-3(tm4559) animals.  
This increase was abolished by the ced-9(n1950) mutation.  The FRET ratios were assayed as in a.  (c) 
Inhibition of HBx-induced cell death by CsA.  The percentage of PLM death in animals treated with 1 
mM CsA was scored as described in Fig. 4.2A.  At least 100 L4 stage larvae from each strain were 
scored.  (d) Inhibition of HBx-induced cytosolic Ca2+ increase by CsA.  The FRET ratio of bzIs17; asp-
3(tm4559); smIs451 animals treated with DMSO or 1 mM CsA was assayed as described in a.  The y axis 
represents average FRET ratio in PLM neurons and error bars represent SEM.  For each strain, at least 15 
neurons were assayed for the FRET ratio (a, b, and d).  The significance of the differences between 
different strains was determined by unpaired t test. * P < 0.05; ** P < 0.005; *** P < 0.0001. 
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Mitochondrial involvement in HBx-induced cell killing and Ca2+ increase. 
Because CED-9 localizes to mitochondria and the mitochondrial permeability transition 
pore (MPTP) has been implicated in mediating HBx-induced Ca2+ increase (74, 98), I tested 
whether MPTP affects HBx-induced cell killing and Ca2+ increase in C. elegans.  I first treated 
smIs98 animals with cyclosporin A (CsA), a peptide that desensitizes MPTP by interacting with 
mitochondrial cyclophilins, regulators of MPTP (123).  In smIs98 animals normally missing 50% 
of PLM neurons, 1 mM CsA treatment reduced the percentage of missing PLM to 15% (Fig. 
4.6c), indicating that MPTP is involved in HBx-induced cell killing.  Moreover, loss of ced-3 
enhanced suppression of HBx-induced cell killing by CsA (from 15% PLM death in CsA-treated 
animals to 4% PLM death; Fig. 4.6c), whereas loss of either clp-1 or mec-6 did not enhance 
suppression of PLM death by CsA (Fig. 4.6c).  These results indicate that MPTP is critical for 
HBx-induced necrotic cell death. 
 
I then examined whether MPTP is involved in HBx-induced cytosolic Ca2+ increase. I 
found that the FRET ratio of bzIs17; asp-3(tm4559); smIs451 animals treated with CsA was 
reduced to the level seen in bzIs17; asp-3(tm4559) animals (Fig. 4.6d), suggesting that HBx-
induced cytosolic Ca2+ increase was completely suppressed by CsA.  This result also indicates 
that HBx-induced Ca2+ increase is mediated through MPTP.  
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DISCUSSION 
HBV infects more than 400 million people and is the leading cause of liver disease and 
HCC worldwide.  As the key pathogenic and oncogenic protein encoded by HBV, HBx 
presumably interacts with host factors to promote virus replication and various pathogenic 
consequences such as liver cell death and HCC (38, 39, 41). However, its cellular targets and 
mechanisms of action remain unclear, partly due to inherent problems associated with many 
cultured cell studies and the genetic complexity of mammalian systems (for example, mammals 
have at least six Bcl-2-like cell death inhibitors), thereby preventing definitive identification of 
HBx targets.  Therefore, development of a simpler animal model where HBx host factors and 
downstream effectors can be identified and verified through powerful molecular genetic 
approaches becomes imperative for understanding HBx functions and treating chronic HBV 
patients.  In this study, I show that C. elegans, with its much simpler genome (only one Bcl-2 
homolog) and powerful genetic tools, presents one such animal model.  Our finding that 
expression of HBx in C. elegans induces both apoptosis and necrosis, which mimics one of the 
early cellular events following liver infection by HBV (41, 46, 47, 99), leads to systematic 
genetic dissection of HBx-induced cell death pathways that involve highly conserved cell death 
regulators and executors (Fig. 4.2a).  These include key regulators in the central apoptosis 
pathway (CED-9, CED-4, and CED-3) and critical components in the necrosis pathway, 
including regulators of intracellular Ca2+ (CRT-1, CNX-1, UNC-68 and ITR-1), Ca2+-dependent 
proteases (CLP-1 and TRA-3), and their downstream proteases (ASP-3 and ASP-4), many of 
which have not previously been implicated in HBx-induced cell death (Fig. 4.2).  The HBx 
suppressor screen has identified key regulators from both cell death pathways and still has the 
potential to identify new targets or effectors of HBx.   
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Importantly, the cell killing activity of HBx is completely dependent on CED-9, a Bcl-2 
homolog and a key cell death inhibitor, because a gain-of-function mutation (G169E) in the 
BH3-binding pocket of CED-9 completely blocks HBx-induced cell death in C. elegans.  In 
vitro, HBx interacts with CED-9, but not with CED-9(G169E), through its BH3-like motif.  
Alteration of two conserved residues in the BH3-like motif of HBx abolishes binding of HBx to 
CED-9 and HBx’s cell killing activity.  A compensatory mutation (E125A) in the BH3-like motif 
of HBx that restores binding of HBx to CED-9(G169E) allows HBx to kill efficiently in ced-
9(n1950gf) animals.  These in vitro and in vivo results establish that HBx interacts directly with 
CED-9 through its BH3-like motif to induce cell killing, and that CED-9 is the bona fide cellular 
target of HBx.  Moreover, HBx similarly interacts with Bcl-2 and Bcl-xL, two human anti-
apoptotic CED-9 homologs, through its BH3-like motif to induce cell death in human hepatic 
cells, and Bcl-2 can substitute for CED-9 to mediate HBx-induced cell killing in C. elegans.  
These findings indicate that HBx acts through conserved host targets (CED-9 and Bcl-2) and 
conserved signaling pathways to induce cell killing.   These analyses also demonstrate the unique 
advantage of the C. elegans genetic system for unambiguous determination of in vivo protein 
interaction and target identification. 
 
One central signaling event associated with HBx expression in hepatic cells is alteration 
of cytosolic Ca2+, which is critical for HBV replication, transcription and core assembly and is 
involved in activation of cell death and several other signaling pathways (74, 90, 103-107).  
Although the cellular target of HBx-mediated calcium stimulation is unknown, HBx has been 
proposed to target mitochondria to effect permeability transition (44, 74, 98, 101), which plays 
an important role in regulating intracellular Ca2+ homeostasis (124, 125). I show that HBx 
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interacts directly with CED-9, a mitochondrial protein, to increase cytosolic Ca2+, which in turn 
triggers activation of necrosis in C. elegans through Ca2+-dependent proteases (CLP-1 and TRA-
3)(Fig. 4.2b).  Importantly, HBx-induced Ca2+ elevation and necrosis can both be suppressed by 
CsA, an inhibitor of the mitochondria permeability transition pore.  These results are consistent 
with the observations in human cells and indicate that CED-9 is the cellular target of HBx for 
altering intracellular Ca2+ (Fig. 4.2b).  Because Bcl-2 associates with HBx in human cells, can 
substitute for CED-9 in mediating HBx-induced cell killing in C. elegans, and has been 
implicated in regulating mitochondria permeability transition (124, 126), Bcl-2 and related 
family members, many of which are mitochondrial proteins, are likely targeted by HBx to induce 
alteration of Ca2+ signaling, which triggers activation of multiple viral and cellular events, 
including HBV replication, transcription and assembly and cell death.  Therefore, Bcl-2 and 
other family proteins could be major HBx targets and ideal therapeutic intervention point for 
treating HBV-related liver disorders. 
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METHODS 
Strains and Culture conditions.  C. elegans strains were cultured at 20°C using standard 
procedures (62). The N2 Bristol strain was used as the wild-type strain. The following alleles 
were used in the genetic analyses: LGI, mec-6(e1342); LGIII, ced-4(n1162), clp-1(tm690), cnx-
1(nr2009), ced-9(n1950, n2812); LGIV, itr-1(sa73), ced-3(n2433); LGV, crt-1(bz29), unc-
68(e540), egl-1(n3082); LGX, asp-3(tm4559), asp-4(ok2693). Detailed allele information is 
described in Wormbase (www.wormbase.org/). In addition to these strains, bzIs8 is an integrated 
transgene located on LGX and contains a Pmec-4GFP construct, which directs GFP expression in 
six C. elegans touch receptor neurons (54).  smIs98 is an integrated transgene located on LGII 
and contains Pmec-3GFP and Pmec-7HBx constructs.  smIs3 is an integrated transgene containing 
Pmec-3GFP.  bzIs17 is an integrated transgene containing Pmec-4YC2.12, which directs expression of 
the YC2.12 cameleon calcium sensor under the control of the mec-4 gene promoter (121). 
smIs451 is an integrated transgene containing only Pmec-7HBx. All integrated transgenes were 
backcrossed six times with the N2 strain before being used for further genetic analyses. 
 
Heat shock experiments.  Gravid transgenic adults were placed on plates for 2 hours at 20°C to 
let them lay eggs. The plates were then heat-shocked at 33°C for 1 hour and returned to 20°C for 
1 hour before removing all adult worms.  After 24 hours at 20°C, the transgenic embryos were 
scored for embryonic lethality.  
 
EMS mutagenesis.  EMS mutagenesis was carried out as described previously (62). Briefly, 
smIs98; smEx[PhspHBx + PhspGFP] L4 larvae were exposed to 47 mM EMS for 4 hours with 
agitation.  The F1 progeny of mutagenized animals were cloned out, and the F2 embryos were 
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subjected to heat-shock treatment at 33°C for 1 hour and returned to 20°C for 1 hour.  This heat-
shock treatment was repeated 3 more times to ensure 100% killing of embryos by HBx.  The 
surviving larvae with robust GFP expression in many cells were identified as putative suppressor 
mutants, which were subjected to the secondary screen using smIs98.  Only those mutants in 
which HBx-induced touch cell death was completely or partially suppressed were considered as 
true suppressors and analyzed further. 
 
Quantification of PLM killing by HBx.  PLM neurons were scored in L4 larvae in the presence 
of the integrated transgene, smIs98 or bzIs8, using a Nomarski microscope equipped with 
epifluorescence (66). 
 
Transgenic animals.  Germline transformation was performed as described previously (127). 
The PhspHBx constructs (at 25 ng/µl each) were injected into animals with the appropriate genetic 
background using Psur-5GFP (25 ng/µl) as a co-injection marker, which directs GFP expression in 
all somatic cells in most developmental stages (53). The Pmec-7HBx construct or its mutant 
derivatives (25 ng/µl) was injected into bzIs8; unc-76(e911) animals using p76-16B (5 ng/µl) as 
a co-injection marker, which rescues the uncoordinated defect of the unc-76(e911) mutant.  The 
Pmec-7CED-9 or Pmec-7hBcl-2 construct (25 ng/µl) was injected into smIs98; ced-9(n1950) animals 
using pRF4 (50 ng/µl) as a co-injection marker, which causes a roller phenotype in transgenic 
animals. 
 
Molecular biology.  The HBx cDNA clone was kindly provided by Dr. Xiao-Kun Zhang (The 
Burnham Institute for Medical Research). Standard methods of cloning, sequencing, and 
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polymerase chain reaction amplification (PCR) were employed.  Briefly, full-length HBx cDNA 
was subcloned into the pGEX-4T-2 vector via its EcoRI and Not I sites to generate the pGEX-
4T-2-HBx protein expression vector. To make PhspHBx constructs, full-length HBx cDNA was 
subcloned into C. elegans heat shock vectors, pPD49.78 and pPD49.83, via Nhe I and Kpn I 
sites.  Pmec-7HBx was constructed by subcloning HBx cDNA into the pPD52.102 vector via its 
Nhe I and Kpn I sites. To make HBx mammalian expression constructs, Flag-HBx cDNA was 
amplified by PCR and cloned into the pcDNA3.1(+) vector via its Nhe I and EcoRV sites. The 
HBx mutant constructs containing G124L, I127A, E125A or E126A substitutions were generated 
using a QuickChange Site-Directed Mutagenesis kit (Stratagene Inc.) and confirmed by DNA 
sequencing.  To make Bcl-2, Bcl-xL and Bax protein expression vectors, the coding regions for 
human Bcl-2(1-218), human Bcl-xL(1-209), and mouse Bax(1-173) were amplified by PCR and 
subcloned into the pET-19b vector via its Nde I and Xho I sites, respectively. pET-24a-CED-
9(68-251) and pET-24a-CED-9(68-251; G169E) were generated by Parrish et al (116). Pmec-
7CED-9 and Pmec-7hBcl-2 were generated by subcloning the full-length ced-9 and human Bcl-2 
cDNA fragments into the pPD52.102 vector via its Nhe I and EcoR V sites, respectively. 
 
Protein expression and purification.  HBx proteins were expressed in Escherichia coli strain 
BL21(DE3) with a N-terminal GST tag in a pGEX-4T-2 vector (Pharmacia). The soluble fraction 
of the E. coli lysate expressing GST-HBx proteins (wild-type or mutants) was incubated with 
Glutathione Sepharose beads (Pharmacia) and purified GST-HBx proteins were eluted with 10 
mM reduced glutathione (Amersham).  CED-9(68-251), human Bcl-2(1-218), human Bcl-xL(1-
209), and mouse Bax(1-173) proteins were expressed individually in BL21(DE3) as either a C-
terminally or N-terminally six histidine-tagged protein using a pET-24a or pET-19b vector 
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(Novagen), respectively. They were then affinity purified using Talon Metal Affinity Column 
(Clontech) and eluted with 250 mM imidazole. 
 
GST fusion protein pull-down assays.  Purified GST-HBx proteins or GST protein (2.5 µg 
each) immobilized on Glutathione Sepharose beads (Pharmacia) were incubated with 5 µg of 
purified CED-9(68-251)-His6, CED-9(68-251; G169E)-His6, His6-hBcl-2(1-218), His6-hBcl-
xL(1-209), or His6-mBax(1-173) in a binding buffer containing 25 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 0.1% Nonidet P40, 10% glycerol, 1 mM phenylmethylsulphonyl fluoride and 
5 mM dithiothreitol at 4°C for 2 hours. One portion of the incubation mix was analyzed by 
western blot to examine the input levels of GST-HBx proteins and Bcl-2 family proteins using an 
antibody to GST (B-14) or the six histidine tag (H15), respectively (Santa Cruz Biotechnology, 
Inc.).  The Sepharose beads were then washed five times with the same buffer before the bound 
proteins were resolved on a 15% SDS polyacrylamide gel and detected by immunoblotting. 
Structural modeling.  Homology modeling of the complex structure between the HBx Peptide 
(residues 120-128) and CED-9 was performed using the published complex structure between 
the EGL-1 BH3 domain and CED-9 as a template (PDB code: 1TY4).  The model was further 
optimized using the program COOT manually to be reasonable (128). All modeling figures were 
created by the PyMOL program (129) and labeled by Adobe Illustrator CS4.  
 
Cultured cells.  Transfection of HepG2 cells was carried out using Effectene Transfection 
Reagent (Qiagen) following the manufacturer’s protocol. A transfection efficiency of 15 to 30% 
was routinely achieved. All transfection experiments were performed 24 hours after plating. 1 μg 
of pcDNA3.1, pcDNA3.1-Flag-HBx, or pcDNA3.1-Flag-HBx(G124L, I127A) was diluted in 
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100 μl of the DNA-condensation buffer (Buffer EC) supplied by the manufacturer (Qiagen).  8 μl 
of enhancer and 10 μl of Effectene were sequentially added to the mixture, each followed by 
vortexing and incubation at room temperature per manufacture protocol. After that, the mixture 
was supplemented with 0.6 ml complete medium and added to cells.  Co-transfection of an 
enhanced GFP (EGFP)-expressing plasmid pEFGP-C1 (1 μg) was included, where appropriate, 
to monitor transfection efficiency when performing flow cytometry analysis in the cell killing 
assays.  
 
Co-immunoprecipitation Assays.  Coimmunoprecipitation experiments were performed using 
an antibody (M2) to the Flag epitope (Sigma). Briefly, HepG2 cells transfected with different 
pcDNA3.1-Flag-HBx constructs were lysed in lysis buffer (100 mM NaCl, 0.5 mM MgCl2, 0.15 
mM CaCl2, 1% (v/v) NP-40, 10 mM Tris-HCl, pH 8.0) containing protease inhibitor cocktail 
tablets (Roche), and cell debris was removed by centrifugation at 10,000 g for 10 minutes at 4°C. 
The cell lysate was precleared with Protein G Sepharose beads (GE healthcare) and subsequently 
incubated with the M2 antibody for 1 hour with gentle shaking at 4oC.  Protein G Sepharose 
beads were then added and the incubation was continued for another 2 hours. The beads were 
then washed five times with the lysis buffer. The bound proteins were resolved on a 15% SDS 
polyacrylamide gel and detected by immunoblotting. 
 
Flow cytometry (FACS) analysis.   36 hours post-transfection, living and dead HepG2 cells 
were scraped into the cell growth medium and precipiated by centrifugation. Cells from one well 
of a six-well plate (~6 x 105 cells) were washed in cold PBS for two times and resuspended in 
600 µl Annexin V-binding buffer (10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4). 
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Labeling of cells by propidium iodide (Sigma) and Annexin-V pacific blue (Invitrogen) was 
carried out according to the protocol provided by Invitrogen.  Briefly, 100 µl of the suspended 
cells were transferred to a new tube.  5 µl of Annexin-V Pacific Blue (Invitrogen) and 5 µl of 
Propidium Iodide (Sigma) were added to each tube and incubated for 30 min at room 
temperature in the dark.  400 µl of Annexin V-binding buffer were then added to each tube.  
Cells were analyzed on the CyAnTM ADP Analyzer (DakoCytomation) with background gates set 
to exclude non-transfected GFP(-) cells and to restrict Annexin-V Pacific Blue staining alone, or 
Propidium Iodide staining alone, to fewer than 0.5% positive events. Data were collected from 
more than 10,000 cells for each sample.  
 
Chemical treatment of C. elegans.  I treated the worms with chemicals using an oil-base 
protocol described previously (130).  Briefly, I first dissolved Thapsigargin (Sigma) or 
Cyclosporin A (Sigma) in DMSO and then diluted it in 100% soybean oil (Crisco). I placed L4 
larval stage hermaphrodite animals onto standard NGM plates seeded with OP50. Oil solutions 
containing the chemicals were spread (0.8-1 ml) onto each plate so that the NGM surface was 
completely covered by oil.  Worms lived at the interface of the NGM medium and the oil.  I then 
examined their F1 progeny for PLM cell death or the FRET ratio in PLMs.  
 
Calcium imaging and analysis.  A C. elegans strain with an integrated Pmec-4YC2.12 cameleon 
transgene (bzIs17) was used to quantify relative cytosolic calcium levels in PLM neurons (121). 
Animals at the L1 larval stage were immobilized on a 2% agar pad in a solution containing 0.3 
M 2,3-butanedione monoxime and 10 mM HEPES (pH 7.2)(131). PLM neurons were visualized 
using an Axioplan 2 Nomarski Microscope (Zeiss) equipped with a SensiCam CCD camera 
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(PCO Imaging Kelheim, Germany). CFP (427/10-25 excitation, 440 dichroic, 472/30-25 
emission), YFP (504/12-25 excitation, 520 dichroic, 542/27-25 emission), and FRET (427/10-25 
excitation, 440 dichroic, 542/27-25 emission) filters (Semrock), a colliminating emission port 
adapter (Photometrics), and the Slidebook 5.0 software (Intelligent Imaging Innovations) were 
used to collect FRET data.  The CFP channel collects CFP emission after CFP excitation and the 
FRET channel collects YFP emission after CFP excitation. Analysis of exported tiff files 
containing data from the FRET or CFP channel was performed using the ImageJ software (NIH).  
The FRET ratio was calculated by (FRETPLM -FRETbkgnd) / (CFPPLM - CFPbkgnd), where FRETPLM 
and CFPPLM are the mean fluorescent intensities in the FRET and CFP channels of the PLM 
neuron and FRETbkgnd and CFPbkgnd are the mean fluorescent intensities in the FRET and CFP 
channels of a background region adjacent to the PLM neurons (122, 132).  
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CHAPTER V       
The retromer component VPS-29 is important for ectopic cell death induced by HBx in C. 
elegans 
 
 
ABSTRACT 
With over 400 million people chronically infected with the hepatitis B virus (HBV) 
worldwide, it is still unclear how HBV X proteins (HBx) mediate liver pathogenesis. To resolve 
the issue, I have generated an HBx animal model using Caenorhabditis elegans. Here I report the 
identification of the vps-29 gene as an important regulator of HBx induced cell death in C. 
elegans. Loss of vps-29 strongly and specifically reduced HBx induced ectopic cell death. vps-29 
encodes an endosomal protein that is a subunit of the membrane-associated retromer complex 
essential for endosome-to-Golgi retrograde transport and cycling of receptors. Moreover, I found 
that the whole retromer complex including VPS-35 and VPS-26 is involved in HBx induced cell 
death. Genetic analysis reveals that the retromer is a component of the necrosis pathway in C. 
elegans. siRNA knockdown of the mouse vps-29 gene inhibits the stimulating effect of HBx on 
HBV transcription in mice. Overall, our study suggests that retromer is an important mediator of 
HBx that regulates HBV replication and pathogenesis. 
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INTRODUCTION 
Hepatitis B Virus (HBV) infects more than 400 million people in the world and is the 
leading cause of liver cancer and diseases.  It has been a global health issue.  The key pathogenic 
and oncogenic protein encoded by HBV is the 17 kDa novel protein named HBV X protein 
(HBx). As its name implies, HBx is an enigmatic protein that can bind a vast number of proteins 
in various in vitro systems and has been implicated in regulating many different cellular events, 
from virus replication and transcription to numerous signal transduction pathways, intracellular 
calcium homeostasis, proteasome activity, cell cycle progression, and cell death(43, 44, 74, 77-
84, 86, 88-90, 133). As a result, the cellular targets of HBx and its acting mechanisms remain 
elusive, which greatly hinders effective treatment of chronic HBV patients and prevention of 
liver cancer development. 
 
Our C. elegans model expressing HBx protein mimicks its death-inducing activity in 
human hepatocytes. Global expression of HBx in C. elegans induces widespread cell death and 
embryonic lethality and restricted expression of HBx in mechanosensory neurons causes ectopic 
neuronal death (Fig. 4.1). To identify potential cellular targets of HBx, I performed a genetic 
suppressor screen and identified multiple genes important for HBx-induced cell death. Here, I 
report the characterization of vps-29, which is important for the function of HBx in C. elegans 
and encodes a subunit protein of the membrane-associated retromer complex.  
 
The retromer is a complex that associates with the cytosolic face of endosomes and 
mediates retrograde transport of transmembrane cargo from multivesicular bodies to the trans-
Golgi network(134, 135). The retromer complex comprises VPS-26, VPS-29 and VPS-35(134, 
135). Recent studies have implicated the retromer in a broad range of physiological, 
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developmental and pathological processes, underscoring the critical nature of retrograde 
transport mediated by this complex(134-139). 
 
I show that loss of vps-29 function strongly and specifically decreases ectopic cell death 
induced by HBx. The retromer complex, including VPS-29, VPS-35 and VPS-26, is involved in 
HBx induced cell death. Genetic analysis reveals that retromer is involved in the necrosis 
pathway in C. elegans. siRNA knockdown of the mouse vps-29 gene inhibits the stimulating 
effect of HBx on HBV transcription in mice. Thus, the retromer represents an important link 
between HBx functions and necrotic cell death pathway in C. elegans. 
 
 
RESULTS 
An HBx suppressor screen identified in vivo targets or effectors of HBx.   
To identify targets or effectors of HBx-induced cell killing, I conducted a genetic screen 
to isolate suppressors of the embryonic lethality phenotype caused by global expression of HBx 
(Fig. 4.1b).  To facilitate identification of true HBx suppressors, I performed the mutagenesis 
screen in smIs98 (Pmec-7HBx and Pmec-3GFP) animals that co-expressed HBx and GFP under the 
control of the heat-shock promoters (PhspHBx and PhspGFP; Fig. 5.1a). PhspGFP was used to 
eliminate mutations that affected transcription from the heat-shock promoters, while smIs98 
provided the secondary screen for suppressors of HBx-induced cell killing. From a screen of 
approximately 20,000 haploid genomes, I isolated 31 HBx-induced death suppressors, which 
were named hids mutations.  All hids mutations not only suppressed embryonic lethality caused 
by global expression of HBx (PhspHBx) but also reduced or blocked ectopic neuronal death in 
smIs98 animals (Fig. 5.1b). Most hids mutations partially suppressed ectopic PLM death in 
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smIs98 animals, suggesting that they affect either the apoptotic or the necrotic pathway (Fig. 
5.1b).  Indeed, one hids mutation (sm250) failed to complement clp-1(tm690) and is a nonsense 
allele of clp-1 (Trp295 to Opal).  One hids mutant (sm221) failed to complement mec-6(e1342) 
and is a missense allele of mec-6 (Gly77 to Ser).  The third hids mutant (sm224) had no apoptotic 
cell corpse and is a nonsense allele of ced-4 (Glu383 to Ochre).  Since mec-6, clp-1 and ced-4 are 
all well known and important players in the apoptosis and necrosis pathways (Fig. 4.2b) (4, 7), 
these findings indicate that our genetic screen effectively identifies genes involved in HBx-
induced apoptosis and necrosis.  
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Figure 5.1. Identification of cellular effectors or targets of HBx through an HBx suppressor screen. 
(a) Strategy of isolating suppressors of HBx-induced cell death (hids) in C. elegans. smIs98 animals 
carrying both PhspHBx and PhspGFP were mutagenized by ethyl methanesulfonate (EMS).  Embryos from 
the second generation of mutagenized animals were treated with heat-shock.  GFP-expressing animals 
that survived the heat-shock treatment were selected (“X” indicates dying embryos) and analyzed further 
for suppression of PLM death using smIs98.  Only those mutants that displayed significant suppression of 
PLM death are considered as true hids mutants. (b) Characterization of three hids mutants. sm221, sm224 
and sm250 were found to affect mec-6, ced-4 and clp-1, respectively.  The nature of amino acid and 
nucleotide changes is indicated (nucleotide changes are underlined).  At least 200 L4 larvae from each 
suppressor strain were scored.  
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sm216 suppresses ectopic cell death induced by HBx 
From the hids suppressor screen, I also isolated two recessive alleles, sm216 and sm222, 
which were mapped to chromosome III and failed to complement each other, suggesting that 
they affect the same gene. I first examined PLM survival in smIs98; sm216 animals. I found that 
the number of surviving PLM neurons is significantly higher in smIs98; sm216 animals than in 
smIs98 animals (Table 5.1). For example, 50% of PLM neurons in smIs98 animals underwent 
ectopic cell death, whereas only 16% of PLM neurons in smIs98; sm216 mutant animals 
underwent cell death. Consistently, sm216 also partially suppressed the embryonic lethality 
phenotype caused by global expression of HBx in C. elegans (Table 5.1). This indicates that the 
sm216 mutation suppresses HBx cell-killing activity. 
 
Table 5.1 vps-29 alleles reduce ectopic cell death induced by HBx 
Genotype % Missing PLMs in smIs98 § % Embryonic lethality in smEx[PhspHBx] §¶ 
Wild type 50% 98% 
vps-29(sm216) 16% 40% 
vps-29(sm222) 16% 42% 
vps-29(tm1320) 15% 39% 
§The percentage of missing PLMs and embryonic lethality were scored as described in Materials and Methods. 
¶Upon heat shock treatment (fresh laid HBx transgenic embryos were heat-shocked at 330C for 1 hour) 
 
 
sm216 causes a nonsense mutation in C. elegans VPS-29 protein 
Since sm216 is an effective HBx suppressor and does not cause any discernable 
phenotype on its own, I mapped and cloned the gene affected by sm216. Briefly, I mapped 
sm216 to Linkage Group III (LGIII) between two genetic markers, unc-32 and dpy-18, at a 
position ~10.02 Mb or  ~1.70 cM. Transformation rescue experiments showed that three fosmids 
in the mapped region, 16bB10, 33aC06 and 26dF04, when injected together, fully rescued 
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reduced cell death phenotype of the sm216 mutant (Fig. 5.2), indicating that a muation in the 
coverd region is responsible for HBx cell killing suppression. 
 
To identify the gene affected by sm216, I carried out germline transformations of smIs98; 
sm216 animals with three fosmids (16bB10, 33aC06, and 26dF04) individually. Only fosmid 
26dF04 showed rescue of the reduced cell death phenotype of the sm216 mutant. Analysis of the 
26dF04 subclones indicates that a single ORF, zk1128.8, which encodes a central component of 
the retromer complex VPS-29, is responsible for the rescue activity (Fig. 5.2). 
 
Sequencing of genomic DNA from the sm216 mutant revealed a single nucleotide 
substitution (C-to-T transition) in the third exon of vps-29 that results in a nonsense 
mutation(Q90amber)(Fig. 5.2). The other vps-29 allele, sm222, also is a nonsense mutation 
(Q97amber).  I obtained one deletion allele of vps-29, tm1320, which removes part of exon 3, all 
of intron 3 and exon 4, and part of the 3’UTR of vps-29 (Fig. 5.2) and is a predicted null allele.  
tm1320, like sm216 and sm222, causes a significant reduction of PLM death (15%) in smIs98 
animals, suggesting that all three vps-29 mutations affect HBx cell killing activity (Fig. 5.2). 
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Figure 5.2 Mapping and rescue of the sm216 mutant. (a) Cloning of the gene affected by the sm216 
mutation. The mapped position of sm216 on LG III and results of transformation rescue of the sm216 
mutant by various fosmids and constructs are shown. Missing PLMs percentage in smIs98 background 
was scored (more than 100 for each line). For each fosmid or construct the number of independent 
transgenic lines that showed rescue and the number of transgenic lines tested are shown. The number of 
rescued lines versus total lines generated is indicated to the right. vps-29 ORFs in this region are indicated 
with boxes representing exons and lines representing intronic sequences. The positions of the sm216 and 
sm222 mutation are indicated with an arrowhead. The deletion alleles (tm1320) of vps-29 and the vps-29 
regions removed by this mutation are represented below the vps-29 ORF. (b) Alignment of the VPS-29 
protein sequences from different species (C. elegans, C. briggsae, mouse and human). Identical residues 
are shaded in black, and similar residues in grey. Residues that are identical in all three proteins are 
marked with an asterisk. The mutations identified in the vps-29(sm216) and vps-29(sm222) mutants are 
indicated. 
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vps-29 encodes a protein that is a subunit of the membrane associated retromer complex 
vps-29 encodes an endosomal protein that is a subunit of the membrane-associated 
retromer complex essential for endosome-to-Golgi retrograde transport (134, 135). VPS-29 
forms a retromer subcomplex with VPS-35 and VPS-26 that selects cargo proteins for 
endosome-to-Golgi retrieval, and cellular organelles to plasma membrane transportation (134, 
135). The retromer mediates a wide range of cellular processes, including transport of 
intracellular sorting receptors such as Vps10 in yeast and cation-independent mannose 6-
phosphate receptor (CI-MPR) in mammals(136, 137), formation of Wnt gradients in C. elegans 
and Drosophila (138, 139), and transcytosis of the polymeric immunoglobulin receptor in 
polarized epithelial cells (134, 135). Retromer-mediated cycling of receptors is probably 
achieved by interaction of cargoes with different retromer subunits or between cargoes and a 
retromer partner like Grd19/Snx3 (134, 135). 
 
The retromer complex is involved in HBx induced ectopic cell death 
Since VPS-29 is the important scaffolding protein of the retromer complex, I tested 
whether other components of the retromer complex are involved in HBx induced cell death. I 
found that loss of vps-26 and vps-35 suppressed HBx-induced cell death (from 50% PLM death 
to 18-19% PLM death; Table 5.2). Thus, each individual retromer component is necessary for 
HBx-induced cell death in C. elegans. 
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Table 5.2 The retromer affects ectopic cell death induced by HBx 
Genotype % Missing PLMs in smIs98 § % Embryonic lethality in smEx[Phsp::HBx] §¶ 
Wild type 50% 98% 
vps-29(tm1320) 15% 39% 
vps-35(ok1880) 19% 45% 
vps-26(tm1523) 18% 41% 
§The percentage of missing PLMs and embryonic lethality were scored as described in Materials and Methods. 
¶Upon heat shock treatment(fresh laid HBx transgenic embryos were heat-shocked at 330C for 1 hour) 
 
 
Retromer acts in the necrotic cell death pathway 
To understand how the retromer complex affects ectopic cell death induced by HBx, I 
carried out genetic analysis to determine the relationships between vps-29 and key regulators of 
apoptosis and necrotic cell death. In particular, I focus on the apoptosis executor ced-3 and the 
necrosis mediator mec-6 (3), (108). vps-29(tm1320) specifically enhanced suppression of HBx-
induced cell death by strong lf mutations in the ced-3 gene, which is the only caspase in the 
apoptosis pathway of C. elegans, but not that caused by mutations in the mec-6 gene, which acts 
in a necrotic cell death pathway (Table 5.3). These results indicate that HBx acts in the necrotic 
cell death pathway. 
 
Table 5.3 vps-29 act in the necrotic cell death pathway induced by HBx 
Genotype % Missing PLMs in smIs98 § 
Wild type 50% 
vps-29(tm1320) 15% 
ced-3(n2433) 26% 
vps-29(sm222); ced-3(n2433) 9% 
mec-6(e1342) 9% 
vps-29(tm1342); mec-6(e1342) 10% 
§The percentage of missing PLMs were scored as described in Materials and Methods, at least 200 animals were counted for each 
strain. 
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Loss of vps-29 suppresses necrotic cell death 
           I next determined whether vps-29 deficiency is protective against other necrotic cell 
deaths. In Caenorhabditis elegans, gain-of-function mutations in specific ion channel genes such 
as the degenerin genes deg-1 and mec-4, the acetylcholine receptor channel subunit gene deg-3 
and the Gs protein α subunit gene gsa-1 evoke necrotic cell death in neurons (111, 140-142). 
First, I investigated whether mutations in C. elegans vps-29 protect against mec-4(u231)-induced 
necrotic death of touch-receptor neurons. In the vps-29(tm1320); mec-4(u231) double mutant, 
vps-29(tm1320) significantly reduced mec-4(u231)-induced necrotic death of touch-receptor 
neurons(Fig. 5.3a). Similarly, vps-29(tm1320) reduced deg-1(u38), deg-3(u662) or Gαs(const) 
induced necrotic death(Fig. 5.3b, c, d). Taken together, these results suggest that the retromer 
protein VPS-29 is important for necrotic cell deaths in C. elegans. 
 
 
Figure 5.3 VPS-29 deficiencies suppress necrotic cell death in C. elegans. (a), Number of vacuolated 
touch receptors at the L1 stage per 100 animals carrying the gain of function allele mec-4(u231) in genetic 
backgrounds of wild-type or vps-29(tm1320) (Data is presented as mean ± S.E.M, n=200,  **, P < 0.0001, 
unpaired t-test). (b), Vacuolated PVC interneurons at the L1 stage per 100 animals carrying the gain of 
function allele deg-1(u38) in genetic backgrounds of wild-type or vps-29(tm1320)  (Data is presented as 
mean ± S.E.M., n=200,  **, P < 0.0001, unpaired t-test). (c), Vacuolated IL1 sensory neurons and PVC 
interneurons per 100 L1 deg-3(u662) gain of function mutant larvae in genetic backgrounds of wild-type 
or vps-29(tm1320)  (Data is presented as mean ± S.E.M., n=200,  **, P < 0.0001, unpaired t-test). (d), 
Vacuolated PVC interneurons at the L1 stage per 100 nuIs5[pglr-1::Gαs(Q227L)] animals in genetic 
backgrounds of wild-type or vps-29(tm1320) (Data is presented as mean ± S.E.M., n=200,  **, P < 
0.0001, unpaired t-test). 
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siRNA knockdown of vps-29 inhibits the stimulating effect of HBx on HBV transcription in 
mouse 
To confirm what I found in C. elegans is relevant to HBV biology in humans, our 
collaborator assayed the effect of VPS-29 on HBx functions in mice.  It has been suggested that 
HBx can augment HBV transcription in mouse by hydrodynamic injection study(143, 144). Our 
collaborator found that knockdown of VPS-29 in mouse by siRNA significantly inhibits the 
stimulating effect of HBx on HBV transcription (data not shown). Therefore, VPS-29 also 
functions as a positive regulator of the HBx activity and HBV transcription in mice, which is 
consistent with what I found in C. elegans. 
 
DISCUSSION 
The retromer complex mediates a wide range of cellular processes, including transport of 
intracellular sorting receptors such as Vps10 in yeast and CI-MPR (cation-independent mannose 
6-phosphate receptor) in mammals, formation of Wnt gradients in C. elegans and Drosophila, 
and transcytosis of the polymeric immunoglobulin receptor in polarized epithelial cells. 
Retromer-mediated cycling of receptors is probably achieved by interaction of cargoes with 
different retromer subunits or between cargoes and a retromer partner like Grd19/Snx3. Our 
findings establish that the retromer is important for necrotic cell death induced by HBx. Thus it 
is possible that the retromer mediates cycling of some cargo proteins important for necrosis 
between the plasma membrane and intracellular organelles. Given the fact that siRNA knock 
down of vps-29 in mouse inhibits the stimulating effect of HBx on HBV transcription, the 
putative cargo proteins could be important in other important cellular events than necrosis, which 
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are required for HBx and HBV functions.  Based on my previous study, the putative cargo 
proteins could be Bcl-2 family proteins, which is worth investigating. Therefore, VPS-29 and 
other retromer complex components could be new targets of therapeutic intervention for treating 
HBV-related liver disorders. Future experiments are needed to identify and characterize the 
cargo proteins involved in HBx induced cell killing and recycled by the retromer complex. 
 
 
 
METHODS 
Strains and Culture conditions.  Strains of C. elegans were cultured at 20°C using standard 
procedures (62). The N2 Bristol strain was used as the wild-type strain. The following alleles 
were used in the genetic analysis: LGI, mec-6(e1342); LGII, vps-35(ok1880); LGIII, vps-
29(sm216/sm222/tm1320); LGIV, ced-3(n2433); LGV, vps-26(tm1523), deg-3(u662); LGX, 
mec-4(u231), deg-1(u38). Allele information is described in Wormbase 
(http://www.wormbase.org/). smIs98 is an integrated transgenic array located on LG II and 
contains Pmec-3::gfp and Pmec-7::HBx constructs. nuIs5 is an integrated transgenic array that 
contains Pmec-7::αs(gf) and Pglr-1::gfp constructs(142).  They were backcrossed eight times with N2 
Bristol strain before being used for genetic analysis. 
 
EMS mutagenesis.  EMS mutagenesis was carried out as described previously (62). Briefly, 
smIs98; smEx[PhspHBx + PhspGFP] L4 larvae were exposed to 47 mM EMS for 4 hours with 
agitation.  The F1 progeny of mutagenized animals were cloned out, and the F2 embryos were 
subjected to heat-shock treatment at 33°C for 1 hour and returned to 20°C for 1 hour.  This heat-
shock treatment was repeated 3 more times to ensure 100% killing of embryos by HBx.  The 
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surviving larvae with robust GFP expression in many cells were identified as putative suppressor 
mutants, which were subjected to the secondary screen using smIs98.  Only those mutants in 
which HBx-induced touch cell death was completely or partially suppressed were considered as 
true suppressors and analyzed further. 
 
Quantification of PLM killing by HBx.  PLM neurons were scored in L4 larvae in the presence 
of the integrated transgene, smIs98 or bzIs8, using a Nomarski microscope equipped with 
epifluorescence (66). 
 
Transgenic animals. Germline transformation was performed as described previ- ously (127). 
Fosmid DNA and rescuing DNA fragments (10 ng/μL each) were injected into smIs98; sm216 
animals using pRF4 (50 ng/µl) as a coinjection marker, which causes a roller phenotype in 
transgenic animals. 
 
Necrotic cell death assays. Necrotic cell death was generally scored during the L1 larval stage.  
Briefly, I prepared L1 larvae by picking gravid adult worms on plates, allowing them lay eggs to 
hatch for 2 hrs before removing the adult worms, and scoring the hatched L1 worms after 12 hrs. 
For the strains expressing mec-4(d), I scored necrosis by the characteristic vacuolated appearance 
of the six touch receptor neurons using Nomarski microscopy. For deg-1(d) and Gαs(gf), I scored 
vacuolation of the two PVC interneurons in the tail, and for deg-3(d) animals, I scored 
vacuolation of IL1 sensory neurons in the head and two PVC interneurons in the tail. 
 
 
 97 
Mouse Study. C57BL/6 mice (male, 6 to 7 weeks old) were anesthetized with ketamine and 
xylazine. Ten micrograms of HBV plasmid DNA were injected into the tail veins of mice within 
5 seconds in a volume of PBS equivalent to 8% of the mouse body weight. The hydrodynamic 
injection study is performed as described before(143, 144). 
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CHAPTER VI  
Conclusions and future directions 
 
CSP-3 is a novel caspase inhibitor 
Given the critical role of apoptosis in animal development and tissue homeostasis, the 
regulation of cell death activation, especially the activation of caspases, has been one of the most 
important issues in biology and clinical medicine. To ensure proper animal development and 
tissue homeostasis, it is imperative that the activation of caspases and their activities are tightly 
controlled. In mammals and fruitflies, a conserved family of proteins, inhibitors of apoptosis 
(IAPs), play crucial roles in inhibiting both the activation of caspases and the activities of 
caspases. Intriguingly, there is so far no IAP homologue or direct caspase inhibitor identified in 
C. elegans, a prototype of apoptosis research where key components of apoptosis have been 
shown to be highly conserved. It is thus enigmatic how the activity of the CED-3 caspase, the 
key cell killing protein, is controlled in C. elegans so that it is prevented from inadvertent 
activation in cells that normally live. My study provides the long-waited answer to this 
tantalizing question and a novel mechanism by which the activation of caspases can be regulated 
in general. My key findings are summarized below: 
 
First, I found that the csp-3 gene, which encodes a protein with sequence similarity only 
to the small subunit of the CED-3 caspase, is a cell death inhibitor in C. elegans.  I characterized 
the loss-of-function phenotypes of the csp-3 gene and found that csp-3 mutants have widespread, 
ectopic cell deaths. Interestingly, the increased cell deaths observed in csp-3 mutant animals are 
due to ectopic deaths of cells that normally live.  These results suggest that CSP-3 is a novel cell 
death inhibitor that acts by protecting cells that normally live from undergoing apoptosis. 
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Second, I demonstrated that CSP-3 interacts physically with the CED-3 zymogen both in 
vitro and in vivo.  Further biochemical analysis indicates that CSP-3 directly binds the CED-3 
zymogen through its large subunit (p17) region, suggesting that CSP-3 may block the interaction 
of the small subunit (p13) of CED-3 with its large subunit (p17), which is critical for CED-3 
activation and protease activity.  Importantly, a single amino acid substitution in CSP-3, Phe 57 
to Glu, significantly reduces the binding of CSP-3 to the CED-3 zymogen in vitro and the 
apoptosis inhibitory activity of CSP-3 in vivo, suggesting that binding of CSP-3 to CED-3 is 
critical for its function and that CSP-3 inhibits apoptosis through association with CED-3. 
 
Finally, I found that CSP-3 specifically inhibits the proteolytic activation of the CED-3 
zymogen but not the activity of the activated CED-3 protease. CSP-3 can inhibit both the auto-
activation of the CED-3 zymogen and the activation of the CED-3 zymogen induced by 
tetrameric CED-4.  Consistently, the mutation in CSP-3 (F57D) that weakens the binding of 
CSP-3 to CED-3 significantly reduces the ability of CSP-3 to inhibit the activation of the CED-3 
zymogen.  Interestingly, CSP-3 fails to inhibit the activity of the active CED-3 protease, 
suggesting that once the active CED-3 p13/p17 heterodimeric complex is formed, the CED-3 
protease is resistant to the inhibition of CSP-3. To our knowledge, this is the first caspase 
inhibitor that selectively inhibits the activation step of the zymogen. Our finding also reveals a 
novel mechanism by which caspase activation can be regulated in general. 
 
Although I have suggested that CSP-3 is functionally similar to IAPs in higher 
organisms, it will be interesting to study whether the caspase-like molecules that have been 
identified in mammals have similar function. In mammals, several caspase-like molecules have 
been identified. Some have only part of caspase domains (e.g. COP, inhibitory CARD INCA and 
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ICEBERG)(145-147), whereas others resemble full-length caspases but lack enzymatic activity 
(e.g. c-FLIP)(148). The mechanism by which CSP-3 inhibits CED-3 activation is novel -- CSP-3 
mimics the CED-3 small subunit, binding and sequestering inactive CED-3 monomers to prevent 
CED-3 dimerization. In mammals, those caspase-like proteins might use a similar mechanism to 
inhibit caspase zymogen activation.   
 
csp-2 protects germ cells from apoptosis 
Although our study of CSP-3 reveals a novel mechanism by which apoptosis and 
caspases can be negatively regulated at the step of caspase activation, it is not clear whether this 
is a rare example of cell death inhibition or a generally applicable scheme for apoptosis 
regulation. 
 
I then report that a second C. elegans caspase homologue CSP-2, which differs from 
CSP-3 in the domain structure, employs exactly the same mechanism to inhibit CED-3 
autoactivation and apoptosis in a different tissue, the C. elegans germline.  Our observation thus 
indicates that this could be a general strategy for negative regulation of caspase activation and 
apoptosis. Our key findings are summarized below: 
 
First, I found that the csp-2 gene, which encodes the second worm caspase homologue, 
acts as a germ-cell-specific apoptosis inhibitor in C. elegans. During C. elegans oocyte 
development, approximately half of all developing germ cells undergo apoptosis, mediated by 
the same core apoptotic machinery composed of CED-3, CED-4 and CED-9.  Yet, the caspase 
inhibitor CSP-3 affects only apoptosis in somatic cells and does not inhibit apoptosis in germ 
cells, raising an intriguing question of how the CED-3 caspase activity is negatively regulated in 
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germ cells.  CSP-2 displays sequence similarity to both the large and the small subunit of the 
CED-3 caspase, yet does not possess a caspase activity, suggesting that it may act as a caspase 
inhibitor like CSP-3. Indeed, by analyzing the loss-of-function phenotypes of the csp-2 mutants, 
I found that loss of csp-2 results in increased cell deaths only in germ cells and not in somatic 
cells, opposite to what I observed with the csp-3(lf) mutants. These results suggest that CSP-2 
and CSP-3 act specifically in germ cells and somatic cells, respectively, to inhibit apoptosis. 
 
Then I demonstrated that CSP-2 specifically inhibits the auto-activation of the CED-3 
zymogen through association with the CED-3 zymogen.  Our biochemical analysis indicates that 
CSP-2 directly binds the CED-3 zymogen through both its large subunit (p17) region and its 
small subunit (p13). Importantly, three amino acid substitutions in CSP-2 (W131E, L132R, 
F186D) almost completely abolish the binding of CSP-2 to the CED-3 zymogen in vitro and the 
apoptosis inhibitory activity of CSP-2 in vivo, suggesting that binding of CSP-2B to CED-3 is 
critical for its function and that CSP-2B inhibits apoptosis through association with CED-3.  
Moreover, I found that CSP-2 acts exactly like CSP-3:  it complexes with the CED-3 zymogen 
and inhibits its auto-activation, but is unable to block CED-4-induced CED-3 activation or the 
activity of active CED-3.  These results establish CSP-2 as the second caspase inhibitor in C. 
elegans that acts specifically to inhibit autoactivation of CED-3 and thus apoptosis. 
 
I are excited about these findings, since this is the first example that an organism utilizes 
two different caspase homologs to inhibit inadvertent caspase auto-activation and apoptosis in 
different tissues (somatic cells and germ cells, respectively). The repeated use of this unique 
strategy to negatively regulate CED-3 caspase activity in C. elegans underscores the importance 
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of keeping caspases in check in living cells and will have a broad implication for caspase 
regulation in higher organisms.  
 
In any cell that is capable of undergoing apoptosis, inadvertent caspase autoactivation is 
possible. Several mechanisms have evolved to deal with this problem, ranging from modulators 
of upstream pro-death signals, to proteins that sequester monomeric pro-caspases, to enzymatic 
inhibitors. In C. elegans, spontaneous, inappropriate CED-3 activation in somatic or germ cells is 
effectively prevented by the presence of CSP-3 or CSP-2, respectively. Thus, nematodes 
overcome the absence of IAPs or IAP-like proteins via caspase-like proteins. However the cell 
death phenotypes of csp-3(lf) or csp-2(lf) animals are relatively weak, it is highly likely that there 
are other caspase or apoptosis regulators in C. elegans and they simply have not yet been 
identified because of the relatively weak phenotypes. It will be of great interests to identify these 
other caspase or apoptosis regulators in C. elegans. The picture of cell death field will become 
increasingly intricate as additional pro-apoptotic and anti-apoptotic regulators are identified and 
their roles are revealed. I are currently working on identifying and characterizing new caspase 
and apoptosis inhibitors in C. elegans. 
 
Bcl-2 is the cellular target of HBx 
HBV infects more than 400 million people in the world and is the leading cause of HCC 
and other liver diseases.  It has been a major health issue in many countries.  The key pathogenic 
and oncogenic protein encoded by HBV is the 17-kDa HBx. As appropriately implied by its 
name, HBx is an enigmatic protein that can bind a vast number of proteins in various in vitro 
systems and has been implicated in regulating diverse cellular events, from virus replication and 
transcription to multiple signal transduction pathways. However, due to inherent problems 
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associated with cultured cell studies and the genetic complexity of mammalian systems (for 
example, mammals have at least six Bcl-2-like cell death inhibitors), it has been very difficult to 
definitively identify the actual cellular targets of HBx and its mechanisms of action.  Therefore, 
development of a simpler animal model where HBx host factors and downstream effectors can 
be identified and verified through powerful molecular genetic approaches becomes imperative 
for understanding HBx functions and treating chronic HBV patients. 
 
Here I report the first study using C. elegans as an animal model to address these long 
unresolved issues.  I not only successfully identify the key cellular target of HBx, but also 
systematically dissect its downstream cell death pathways.  These findings will provide exciting 
conceptual advances in the fields of HBV, apoptosis, necrosis, and calcium signaling. 
 
I established a simple but powerful C. elegans animal model for studying HBx and HBV.  
I found that HBx induces both apoptosis and necrosis in C. elegans, mimicking one of the early 
cellular events of HBV infection.  Taking advantage of the powerful genetic tools in C. elegans, 
I systematically dissect HBx-mediated cell death pathways and have identified conserved 
molecular components that mediate or promote HBx-induced cell death.  These include key 
regulators in the central apoptosis pathway (CED-9, CED-4, and CED-3) and critical 
components in the necrosis pathway, including regulators of intracellular Ca2+ (CRT-1, CNX-1, 
UNC-68 and ITR-1), Ca2+-dependent proteases (CLP-1 and TRA-3), and their downstream 
proteases (ASP-3 and ASP-4), many of which have not previously been implicated in HBx-
induced cell death. Moreover, our genetic screen for suppressors of HBx-induced cell death has 
identified key regulators from both cell death pathways (ced-4, clp-1 and mec-6) and potential 
new targets or effectors of HBx.  Our study demonstrates that C. elegans, with its much simpler 
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genome (only one Bcl-2 homolog) and powerful genetic tools, presents an excellent animal 
model for identifying cellular targets, effectors, and signaling pathways of HBx and HBV. 
 
The Bcl-2 homolog CED-9 is a cellular target of HBx, which contains a BH3-like motif. 
One of the most important findings in this thesis is the unexpected discovery that the cell killing 
activity of HBx is completely dependent on CED-9, a key cell death inhibitor.  I find that a gain-
of-function mutation (G169E) in the BH3-binding pocket of CED-9 completely blocks HBx-
induced cell killing in C. elegans.  In vitro, HBx interacts with CED-9, but not with CED-
9(G169E), through its BH3-like motif. Alteration of two conserved residues in the BH3-like 
motif of HBx abolishes binding of HBx to CED-9 and HBx’s cell killing activity. A 
compensatory mutation (E125A) in the BH3-like motif of HBx that restores binding of HBx to 
CED-9(G169E) allows HBx to kill efficiently in ced-9(n1950gf) animals that express only CED-
9(G169E).  These in vitro and in vivo results establish that HBx interacts directly with CED-9 
through its BH3-like motif to induce cell killing in C. elegans and that CED-9 is the bona fide 
cellular target of HBx for cell killing.  Of note, this kind of compelling genetic and biochemical 
analysis is not possible in the complicated mammalian systems, which have at least six Bcl-2-
like cell death inhibitors (versus only one Bcl-2 homolog in C. elegans), thereby precluding the 
possibility of HBx target identification in mammals.  To our knowledge, this is also the first in 
vivo demonstration that a viral protein causes pathogenesis through a BH3-like motif. 
 
Bcl-2-like cell death inhibitors are conserved cellular targets of HBx.  Importantly, Bcl-2 
and Bcl-xL, two anti-apoptotic human homologs of CED-9, associate with HBx in human 
hepatic cells, and these associations are critical for HBx-induced apoptosis and necrosis in 
human cells.  Strikingly, Bcl-2 can substitute for CED-9 to mediate HBx-induced cell killing in 
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C. elegans.  These results strongly suggest that HBx induces cell death by targeting conserved 
host factors (CED-9 and Bcl-2) and acting through conserved cell killing pathways.  They also 
validate the use of C. elegans as a powerful animal model for identifying host targets, effectors, 
and signaling pathways of HBx/HBV. 
 
CED-9 is a cellular target of HBx-mediated cytosolic calcium increase.  HBx-induced 
alteration of cytosolic Ca2+ is a central signaling event for HBV replication, transcription and 
core assembly and is involved in activation of cell death and several other signaling pathways.  
However, given the vital role of calcium signaling in HBV virology and pathogenesis, the 
cellular target of HBx-mediated calcium stimulation remains unknown. I show that HBx 
interacts directly with CED-9, a mitochondrial protein, to increase cytosolic calcium, which then 
triggers activation of necrosis in C. elegans through calcium-dependent proteases (CLP-1 and 
TRA-3).  Importantly, HBx-induced calcium elevation and necrosis can both be suppressed by 
cyclosporine A, a specific inhibitor of the mitochondria permeability transition pore, which has 
been implicated in regulating intracellular calcium.  These results indicate that CED-9 is the long 
sought-after cellular target of HBx for altering intracellular Ca2+, and mitochondria permeability 
transition is a downstream signaling event that mediates HBx-induced cytosolic calcium 
increase.  Because Bcl-2 associates with HBx in human cells, can substitute for CED-9 in 
mediating HBx-induced cell killing in C. elegans, and has been implicated in regulating 
mitochondria permeability transition, Bcl-2 and related family members, many of which are 
mitochondrial proteins, could be the major HBx targets in mediating key HBV pathogenic 
events, and thus could become the ideal therapeutic intervention point for treating HBV-related 
liver disorders. 
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My thesis work has identified Bcl-2 protein as the cellular target of HBx through which 
HBx induces ectopic cell death. It will be interesting to test whether Bcl-2 is important for the 
other cellular effects that HBx has on the host cells, such as enhancement of HBV infection and 
DNA replication, interference with transcriptional machinery, modulation of proteolytic activity 
and gene expression, and alteration of signaling tranduction cascades. Hopefully, the 
combination of traditional techniques in mammal HBV study and our HBx animal model will 
help address these questions.  
 
Retromer is important for HBx function 
A genetic suppressor screen has been performed in C. elegans to identify HBx regulators 
or effectors. From the screen, I identify the vps-29 gene as an important regulator of HBx 
induced cell death in C. elegans. Loss of vps-29 gene function strongly and specifically reduced 
HBx induced ectopic cell death. vps-29 encodes an endosomal protein that is a subunit of the 
membrane-associated retromer complex essential for endosome-to-Golgi retrograde transport 
and cycling of receptors. Moreover, I found that the whole retromer complex, including its two 
other subunits, VPS-35 and VPS-26, are involved in HBx induced cell death. Genetic analysis 
further suggests that the retromer is important for the general necrosis pathway. Importantly, I 
confirmed that vps-29 is important for HBx mediated HBV replication in mouse and mammalian 
cell culture system. siRNA knockdown of vps-29 inhibits the effect of HBx on HBV 
transcription. Therefore, VPS-29 and other retromer components could be important regulators 
of HBx and a therapeutic intervention point for treating HBV-related liver disorders.  
 
My thesis work has identified the retromer as an important regulator of HBx activity. The 
remaining question is that how retromer is involved in HBx functions. Our current hypothesis is 
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that retromer is important for cell death induced by HBx as well as for HBV functions by 
mediating cycling of some cargo proteins between the plasma membrane and intracellular 
organelles when the cell is infected by HBV. In the future it will be an important step to identify 
and characterize cargo proteins involved in necrosis and HBx functions and recycled by retromer 
complexes. Another potential role of retromer would be the transportation of HBx between 
different organelles inside the cells.  This hypothesis could be tested by comparing HBx 
expression pattern in wild-type and vps-29(lf) backgrounds.  
 
Future prospects 
Our results suggest that C. elegans may be a useful model organism for investigating how 
HBx and HBV functions in human. Our C. elegans model has great potential for genetic 
screening and drug screening. From our genetic screen, there are still more than 20 HBx-induced 
death suppressors. It will also offer great help to HBV field as these additional HBx suppressors 
are cloned and characterized. I will carry out genetic mapping studies to determine the precise 
chromosomal locations of these suppressor genes. Based on the molecular identities of the 
suppressor genes, I will design the next stage experiments to test how their gene products 
mediate HBx and HBV functions.  If necessary, I could also perform additional genetic screening 
to identify and characterize more HBx suppressors. 
 
Another possible project is to perform pharmacological screens in our C. elegans model 
to identify small molecule compounds that may be used as lead compounds to treat liver diseases 
caused by HBV. I will test with chemical librares to look for compounds that suppress HBx-
induced cell death. After positive compounds are identified from C. elegans, I will directly test 
candidate compounds on HBx transgenic mice to examine whether they can block, reduce or 
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delay the development of liver disorders in HBx mice. If a compound turns out to be effective in 
treating HBx mice, I will go back to the C. elegans model to look for potential drug targets. In 
this way, it will be very effective in identifying compounds or drugs that can treat liver diseases 
caused by HBV, taking advantage of the C. elegans animal model for rapid drug screens and 
easy target identification. 
 
All these studies should provide much-needed insights into what in vivo HBV targets are 
and how HBx causes liver degeneration and acute and chronic liver diseases. They also could 
lead to identification of new therapeutic targets and drug leads to treat acute and chronic liver 
diseases caused by HBV.  Besides our HBx model, there are an increasing number of examples 
in which human genes associated with diseases are hererologously expressed in C. elegans. In 
the future, such models could be very useful for screening by mutagenesis, RNAi and chemistry 
to identify new drug targets and drug candidates. 
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